

# **UNIVERSITI PUTRA MALAYSIA**


INTERVENTION EFFECTIVENESS TOWARDS IMPROVEMENT ON KNOWLEDGE, HEALTH BELIEFS AND ANTICIPATED HELP-SEEKING FOR OVARIAN CANCER AMONG UNIVERSITY NON-ACADEMIC STAFF IN MALAYSIA

# NAJAT MILAD ALMAHDI

FPSK(P) 2018 30



# INTERVENTION EFFECTIVENESS TOWARDS IMPROVEMENT ON KNOWLEDGE, HEALTH BELIEFS AND ANTICIPATED HELP-SEEKING FOR OVARIAN CANCER AMONG UNIVERSITY NON-ACADEMIC STAFF IN MALAYSIA



Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in Fulfilment of the Requirements for the Degree of Doctor of Philosophy

February 2018



All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia

G



# DEDICATION

To my lovely parents, husband, children and my sisters and brothers for their understanding, encouragement and patience, without whose support and care I wouldn't have realize my dreams in life.



S)

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Doctor of Philosophy

# INTERVENTION EFFECTIVENESS TOWARDS IMPROVEMENT ON KNOWLEDGE, HEALTH BELIEFS AND ANTICIPATED HELP-SEEKING FOR OVARIAN CANCER AMONG UNIVERSITY NON-ACADEMIC STAFF IN MALAYSIA

By

#### NAJAT MILAD ALMAHDI

February 2018

#### Chairman: Rosliza Abdul Manaf, MBBS, MComMed, PhD Faculty: Medicine and Health Sciences

Ovarian cancer (OC) is one of the deadliest gynecological cancer because of late detection of it. Early detection could be promoted by increasing knowledge, and minimizing barriers and improving time of seeking medical help for ovarian cancer symptoms. Previous studies showed low ovarian cancer awareness among working Malaysian women. The main objective of this study was to develop, implement and evaluate the effectiveness of an educational intervention to improve ovarian cancer knowledge, health beliefs, perceived barriers, and anticipated help-seeking among female non-academic staff in Universiti Putra Malaysia (UPM). This is a randomized controlled trial (RCT), considered in three phases. Phase I was a cross sectional study aimed to obtain current data on the knowledge and attitude related to OC among female non-academic staff in UPM. Data was collected from 366 participants. Response rate of 91.5%. About 96.4% of them were Malay, with mean age of 34 years (SD 7.8). A low knowledge was reported by 46.5% of participant which was predicted by age (P=0.01) and having heard or read about OC (P < 0.001). Half of participants showed negative attitude related to OC, which were predicted by marital status (P<0.001), education level (P=0.02), and having heard or read about OC (P=0.02). In Phase II, educational module was developed according to the Health Belief Model (HBM) and validated. The module composed of educational videos, leaflet, and ovarian cancer symptoms checklist diary. In Phase III (RCT), multi-stage random sampling was used to select 305 of female nonacademic staff who were randomly allocated into study groups (157 in the intervention group vs. 148 in the control group at baseline). The response rate were 73.6%. Data was collected at baseline, immediately, and 3 months after intervention using a validated online questionnaire that adapted from Ovarian Cancer Awareness Measures (Ovarian CAM). There was no significant differences in sociodemographic characteristics between intervention and control group. The mean age of participants was 37.8 years (SD 8.1), and the majority were Malay (96.7%). In the intervention group, the mean scores of anticipated help-seeking, knowledge, and confidence in symptom detection had increased significantly from baseline to immediately, and 3 months after intervention

[5.9 (SD 2.6), 6.7 (SD 2.9), 8.8 (SD 1.4), p<0.001], [5.2 (SD 3.3), 12.3 (SD 2.7), 11.17 (SD 2.5), p<0.001], and [2.19 (SD 1.0), 2.5 (SD 0.91), 2.6 (SD 1.0), p=0.001] respectively. Similarly, the mean scores of the three types of perceived barriers had increased significantly after the intervention at baseline, immediately and 3 months which include: emotional barrier [3.14 (SD 0.9), 1.19 (SD 0.9), 1.69 (SD 0.9), p<0.001], practical barrier [1.93 (SD 0.9), 1.79 (SD 0.9), 0.73 (SD 0.8), p<0.001], and service barrier [1.73 (SD 0.8), 1.64 (SD 0.8), 1.62 (SD 0.8), p<0.001]. The mean score of the perceived benefits shows a significant increase after the intervention at baseline, immediately and 3 months [10.9 (SD 2.5), 11.3 (SD 2.5), 11.5 (SD 2.7), p<0.001]. However, the perceived susceptibility mean score showed non-significant increase at the three points of assessments of study [11.8 (SD 2.8) 12.5 (SD 3.6), 12.7 (SD 3.7), p=0.08]. The control group showed no significant changes in all measured aspects. These results provide evidence for the effectiveness of the electronic-based educational intervention in increasing ovarian cancer knowledge, and anticipated help-seeking for ovarian cancer symptoms among Malaysian non-academic staff at UPM. This study suggests that knowledge on ovarian cancer can improve anticipated seeking help behavior for short term duration. In addition, long term effects need to be addressed for promoting ovarian cancer early detection among Malaysian women.

Keywords: ovarian cancer, knowledge, anticipated help-seeking, Malaysia, non-academic

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

# KEBERKESANAN INTERVENSI TERHADAP PENINGKATAN PENGETAHUAN, KEPERCAYAAN KESIHATAN DAN JANGKAAN MENDAPATKAN BANTUAN BAGI KANSER OVARI DALAM KALANGAN STAF BUKAN AKADEMIK DI MALAYSIA

Oleh

#### NAJAT MILAD ALMAHDI

Februari 2018

#### Pengerusi: Rosliza Abdul Manaf, MBBS, MComMed, PhD Fakulti: Perubatan dan Sains Kesihatan

Kanser ovari (OC) adalah salah satu daripada kanser ginekologi yang boleh membawa maut kerana ia lambat dikesan. Pengesanan awal amat digalakkan untuk meningkatkan pengetahuan, mengurangkan halangan dan mempercepatkan wanita mendapatkan bantuan perubatan jika berlaku gejala kanser ovari. Kajian terdahulu menunjukkan kesedaran kanser ovari yang rendah dalam kalangan wanita Malaysia yang bekerja. Objektif utama kajian ini adalah untuk membangunkan, melaksanakan dan menilai kesan intervensi pendidikan kanser ovari untuk meningkatkan pengetahuan tentang kanser ovari, kepercayaan kesihatan, halangan dan jangkaan mendapatkan bantuan bagi simptom kanser ovari dalam kalangan kakitangan wanita di Universiti Putra Malaysia (UPM). Kajian ini adalah percubaan rawak terkawal (RCT) yang mempertimbangkan dalam tiga Fasa. Fasa I adalah kajian keratan rentas yang bertujuan untuk mendapatkan data terkini tentang pengetahuan dan sikap kanser ovari dalam kalangan kakitangan wanita di UPM. Data ini dikumpul daripada 366 peserta. Kadar maklum balas sebanyak 91.5%. Kira-kira 96.4% peserta adalah Melayu, dengan umur 34 tahun (SD 7.8). Pengetahuan adalah dilaporkan rendah sebanyak 46.5% peserta yang diramalkan oleh umur (P = 0.01) dan setelah mendengar atau membaca mengenai OC (P < 0.001). Tahap II adalah pembangunan modul pendidikan yang disesuaikan dan disahkan oleh Model Kepercayaan Kesihatan. Modul ini terdiri dari tiga elemen iaitu video pendidikan, risalah, dan diari senarai semak gejala kanser ovari. Dalam Fasa III (RCT), persampelan rawak pelbagai peringkat telah digunakan untuk memilih 305 kakitangan wanita bukan akademik dan kaedah rawak diperuntukan dalam 2 kumpulan (157 dalam kumpulan intervensi berbanding 148 dalam kumpulan kawalan pada peringkat penilian asas). Kadar maklumbalas sebanyak 73.6%. Dalam kajian ini data dikumpulkan daripada para peserta pada peringkat penilaian asas dan 3 bulan selepas intervensi dengan menggunakan borang soal selidik kepercayaan dan pengesahan yang disesuaikan dari adaptasi daripada Pengukuran Langkah-langkah Kesedaran Kanser Ovarian (Ovarian CAM). Tiada perbezaan yang signifikan dalam kesemua kriteria sosiodemografi peserta kumpulan intervensi dan kawalan. Dalam kumpulan intervensi, skor min untuk jangkaan mendapatkan bantuan, pengetahuan dan keyakinan terhadap pengesanan gejala telah meningkat secara signifikan selepas intervensi pada peringkat penilian asas, kemudiaan dan 3 bulan [5.9 (SD 2.6), 6.7 (SD 2.9), 8.8 (SD 1.4), p<0.001], [5.2 (SD 3.3), 12.3 (SD 2.7), 11.17 (SD 2.5), p<0.001], dan [2.19 (SD 1.0), 2.5 (SD 0.91), 2.6 (SD 1.0), p=0.001] masing-masing. Begitu juga skor min ketiga-tiga halangan yang dirasakan telah meningkat dengan ketara selepas intervensi pada peringkat penilian asas, kemudiaan dan 3 bulan termasuk: halangan emosi [3.14 (SD 0.9), 1.19 (SD 0.9), 1.69 (SD 0.9), p < 0.001], halangan praktikal [1.93 (SD 0.9), 1.79 (SD 0.9),0.73 (SD 0.8), p <0.001] dan halangan perkhidmatan [1.73 (SD 0.8), 1.64 (SD 0.8)), p <0.001]. Min skor faedah yang dirasakan menunjukkan peningkatan yang signifikan selepas intervensi pada peringkat penilaian, kemudiaan dan 3 bulan [10.9 (SD 2.5), 11.3 (SD 2.5), 11.5 (SD 2.7), p <0.001]. Walau bagaimanapun, skor min bagi kecenderungan tidak menunjukkan hubungan signifikan pada tiga peringkat penilian kajian [11.8 (SD 2.8) 12.5 (SD 3.6), 12.7 (SD 3.7), p = 0.08]. Kumpulan kawalan tidak menunjukkan sebarang perubahan ketara dalam semua aspek yang diukur. Keputusan ini memberikan bukti bahawa keberkesanan intervensi pendidikan yang berasaskan elektronik mampu meningkatkan pengetahuan kanser ovari dapat meningkatkan tingdan niat untuk membantu mencari bantuan segera untuk gejala kanser ovari dalam kalangan wanita bekerja di Malaysia. Kajian ini mencadangkan bahawa kanser ovari dapat meningkatkan tingkahlaku penjagaan pencegahan dalam tempoh jangka masa yang pendek. Oleh itu, kesan jangkan panjang bagi mempromosikan pengesanan awal kanser ovary dalam kalangan wanita harus dipertekankan.

Kata kunci: kanser ovari, pengetahuan, jangkaan mendapatkan bantuan, Malaysia, bukan akademik

#### ACKNOWLEDGEMENTS

First of all, I am very grateful to my God (Allah) SBWT for giving me strength and courage to produce this work, which I hope would be useful to potential readers in Malaysia, and elsewhere.

I would like to sincerely express my grateful appreciation and thanks to my supervisor, Dr Rosliza Abdul Manaf for serving as chairman of my supervisory committee even at hardship. I would also like to express my deepest appreciation to my other supervisory committee members, Dr Suriani Ismail and Dr Hayati Kadir for their assistances and guidance. I would also like to thank Professor Dr. Latiffah A. Lattif and Professor Dr. Maimunah Ismail for their support, and encouragement thorough study period. I would especially like to thank the staff in CaRE (Cancer Resources and Education) center at the Faculty of Medicine and Health Sciences/UPM and Dr. Mahrnoosh Aktari for their participation in development of education module. I would like to thank Diyanah Abdul Manaf and Azrin Shah Bin Abu Bakar for her help in data collection and translation. I would especially like to thank all female staff in UPM especially in the following faculties: Faculty of Medicine and Health Sciences; Environment; Education; Food Technology Science; Administrative building, and Research Medical Center for their support when I validate the study instruments, recruited the participants, and collected data for my Ph.D. theses.

I certify that a Thesis Examination Committee has met on 22 February 2018 to conduct the final examination of Najat Milad Almahdi on her thesis entitled "Intervention Effectiveness Towards Improvement on Knowledge, Health Beliefs and Anticipated Help-Seeking for Ovarian Cancer among University Non-Academic Staff in Malaysia" in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Doctor of Philosophy.

Members of the Thesis Examination Committee were as follows:

## Titi Rahmawati binti Hamedon, PhD

Senior Lecturer Faculty of Medicine and Health Sciences Universiti Putra Malaysia (Chairman)

# Zailina binti Hashim, PhD Professor

Faculty of Medicine and Health Sciences Universiti Putra Malaysia (Internal Examiner)

# Hejar binti Abd. Rahman, PhD

Associate Professor Faculty of Medicine and Health Sciences Universiti Putra Malaysia (Internal Examiner)

# Rizanda Machmud, PhD

Professor Andalas University Indonesia (External Examiner)

NOR AINI AB. SHUKOR, PhD Professor and Deputy Dean School of Graduate Studies Universiti Putra Malaysia

Date: 28 June 2018

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

#### Rosliza Abdul Manaf, MBBS, MComMed, PhD

Medical Lecturer Faculty of Medicine and Health Sciences Universiti Putra Malaysia (Chairman)

#### Suriani Ismail, MD, MPH, PhD

Medical Lecturer Faculty of Medicine and Health Sciences Universiti Putra Malaysia (Member)

# Hayati Kadir, MBBchBAO, M.Community Health

Medical Lecturer Faculty of Medicine and Health Sciences Universiti Putra Malaysia (Member)

#### **ROBIAH BINTI YUNUS, PhD** Professor and Dean School of Graduate Studies

Universiti Putra Malaysia

Date:

# **Declaration by graduate student**

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any other institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature:	Date:
Name and Matric No.:	

# **Declaration by Members of Supervisory Committee**

This is to confirm that:

C

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: Name of Chairman of Supervisory Committee:	
Signature: Name of Member of Supervisory Committee:	
Signature: Name of Member of Supervisory Committee:	

# TABLE OF CONTENTS

	rage
ABSTRACT	i
ABSTRAK	iii
ACKNOWLEDGEMENTS	v
APPROVAL	vi
DECLARATION	viii
LIST OF TABLES	xiv
LIST OF FIGURES	xviii
LIST OF ABBREVIATIONS	xix

# CHAPTER

INTR	ODUCTION	1
1.1	Background	1
1.2	Problem Statement	3
1.3	Significance of the Study	4
1.4	Research Questions	5
	1.4.1 Research Questions of Phase I (Cross sectional	
	study)	5
	1.4.2 Research Question of Phase III	5 5
1.5	Research Objectives	6
	1.5.1 General Objectives	6
	1.5.2 Specific Objectives:	6
1.6	Research Hypotheses	6
1.7	Operational Definitions of Study Variables	7
	1.7.1 Dependent Variable	7
	1.7.2 Independent Variables	8
1.8	Definition of Terms	9

2	LITER	ATURE	REVIEW
	2.1	Strategy	of the Literature Review
	2.2	Epidemi	ology of Ovarian Cancer
		2.2.1	Incidence and Mortality Rate of Ovarian Cancer
		2.2.2	Risk Factors for Ovarian Cancer
		2.2.3	Protective Factors for Ovarian Cancer
	2.3	Ovarian	Cancer- from Silent Killer to Symptom Index
	2.4	Screenin	ng for Ovarian Cancer
		2.4.1	Current Methods of Ovarian Cancer Screening
		2.4.2	Using Symptoms to Predict Ovarian Cancer
		2.4.3	Role of Ovarian Cancer Screening in Reducing the
			Mortality
		2.4.4	Challenges and Limitations Ovarian Cancer
			Screening and Early Detection
		2.4.5	Misperceptions Related to Ovarian Cancer Screening
	2.5	Delay in	Ovarian Cancer Diagnosis

# Delay in Ovarian Cancer Diagnosis292.5.1Patient-related Delay in Ovarian Cancer Diagnosis29

	2.5.2	General Model of Total Patient Delay (Andersen'	
		model)	31
	2.5.3	Factors Affecting Patient Delay in Ovarian Cancer	
	~	Diagnosis	33
2.6		g Medical Help for Ovarian Cancer Symptoms	35
	2.6.1	Help-seeking Behaviour	35
	2.6.2	Hypothetical Help-seeking for Symptoms Potential	
		for Ovarian Cancer Symptoms	36
	2.6.3	Determinants Factors for Help-seeking Behavior	
		(passive detection 38behaviour)	38
2.7		n Cancer Awareness	44
	2.7.1	Ovarian Cancer Symptoms Awareness Level	44
•	2.7.2	Predictors of Ovarian Cancer Awareness	48
2.8		f Health Education Interventions in Promoting	
		ness, Help Seeking Behavior Related to Ovarian	10
	Cancer		49
2.9		nic-based intervention	50
2.10		Symptom Diary to Help Early Diagnosis	50
2.11		Beliefs Model (HBM)	51
	2.10.1	Theoretical Concepts of HBM	51
	2.10.2		52
	2.10.3		54
2.12	Conce	ptual Framework	56
	IODOLC		58
3.1		Location	58
3.2		Study (Need Assessment: Cross Sectional Study)	59
	3.2.1	Study Design of Phase I Study	59
	3.2.2	Study Duration of Phase I Study	59
	3.2.3	Sampling Technique for Phase I Study	59
	3.2.4	Sample Size Calculation for Phase I Study	59
	3.2.5	Inclusion and Exclusion Criteria of Phase I Study	60
	3.2.6	Screening and Recruitments for Phase I Study	60
	3.2.7	Instrument for Data Collection for Phase I Study	61
	3.2.8	Quality Control of the Questionnaire of Phase I	62
	3.2.9	Variables in Phase I Study	64
3.3		I Study (Development of intervention Package)	65
	3.3.1	Setting Goals for the Health Education Package.	65
	3.3.2	Designing the Education Package and Developing	
		their Materials	66
	3.3.3	Validity of Health Education Materials	67
3.4	Phase I	II (Randomized Control Trial)	69
	3.4.1	Study Design for Phase III Study	69
	3.4.2	Study Duration for Phase III Study	69
	3.4.3	Study Population for Phase III Study	69
	3.4.4	Sampling Units for Phase III Study	69
	3.4.5	Sample Frame of Subjects for Phase III Study	69
	3.4.6	Inclusion and Exclusion Criteria for Phase III Study	70
	3.4.7	Sample Size Calculation for Phase III Study	70
	3.4.8	Sampling Method for Phase III Study	71

3

# xi

	3.4.9	Screening and Recruitment of Participants for Phase	
		III Study	75
	3.4.10	Implementation of the Intervention and Data	
		Collection Technique for Phase III Study	77
	3.4.11	Participants Retention for Phase III Study	79
	3.4.12	Evaluation of the Educational Intervention in Phase	
		III Study	80
	3.4.13	Data Collection Instrument (Questionnaire) for Phase	
		III Study	80
	3.4.14	Quality and Control of the Questionnaire of Phase III	83
	3.4.15	Data Analaysis of Phase III Study	85
3.5	Ethical	Consideration	86

4	RESU	LT		87
	4.1	Overvie	W	87
	4.2	Result of	of Phase I study (Need Assessment Study)	87
		4.2.1	Response Rate	87
		4.2.2	Checking and Cleaning Data	87
		4.2.3	Descriptive Analysis	87
		4.2.4	Determinants of the Ovarian Cancer Knowledge and	
			Attitude	94
	4.3	Result	of Phase III Study (Randomized Control Trial)	97
		4.3.1	Response Rate	97
		4.3.2	Screening and Cleaning Data	99
		4.3.3	Strategy of Analysis	99
		4.3.4	Characteristics of Respondents at Baseline	99
		4.3.5	Knowledge on Ovarian Cancer at Baseline	101
		4.3.6	Health Beliefs Related to Ovarian Cancer	104
		4.3.7	Factors Associated with Barriers to Seeking Help	107
		4.3.8	Anticipated Help-Seeking for Ovarian Cancer	
			Symptoms at Baseline	109
		4.3.9	Factors Associated with Anticipated Help-Seeking to	
			Ovarian Cancer Symptoms at Baseline	112
		4.3.10	Evaluation of the Effectiveness of the Intervention	
			(Outcomes of intervention)	115
5	DISCU	USSION		150

	0001011		100
5.1	Phase	I (Need Assessment Study)	150
	5.1.1	Knowledge and Attitude Related to Ovarian Cancer	150
	5.1.2	Determinants of Ovarian Cancer Knowledge and	
		Attitude	151
	5.1.3	Conclusion of Phase I Study	152
5.2	Phase 1	III (Randomized Controlled Trial)	153
	5.2.1	Baseline Data	153
	5.2.2	Factors Associated with Help-Seeking for Ovarian	
		Cancer Symptoms	156
	5.2.3	Effectiveness of the Intervention	157

C

6	CON	CLUSION AND RECOMMENDATIONS	160
	6.1	Conclusion	160
	6.2	Strengths and Limitations of the Study	161
	6.3	Recommendations for Future Studies	162
	6.4	Recommendations for Policy Makers	162

REFERENCES APPENDICES BIODATA OF STUDENT LIST OF PUBLICATIONS

 $(\mathbf{C})$ 



# LIST OF TABLES

Table		Page	
2.1	Illustration of randomized clinical trials On effectiveness of different methods of ovarian cancer screening	26	
2.2	Summary of published studies that investigated determinants of anticipated help-seeking behavior	43	
2.3	Summary of published study about ovarian cancer knowledge	47	
2.4	Constructs of HBM and its application to planning a health intervention	54	
3.1	Parameters used for sample size calculation of phase I	60	
3.2	Outcome measure in the intervention pilot study: comparison of the means scores between pre and post intervention	68	
3.3	Parameters used for sample size calculation of Phase III study	71	
3.4	Random assigns of A and B for the two campuses	74	
3.5	The selected faculties from the south and north campuses	75	
3.6	Level of internal consistency (Alpha value) for each scale of the questionnaire of phase III (n=25)	84	
3.7	Different magnitudes of mean differences using Cohen's criteria	86	
4.1	Sociodemographic characteristics of respondents	88	
4.2	Personal and family medical background characteristics of participants	88	
4.3	Familiarity of participants with ovarian cancer	89	
4.4	Source of information for participant had heard about ovarian cancer	89	
4.5	Knowledge on symptoms (items 1-6) of ovarian cancer for participants	90	
4.6	Knowledge of risk factors for ovarian cancer for participants (items from 7-13)	91	
4.7	Knowledge on screening and early detection of ovarian cancer (items 14-17)	91	
4.8	Mean score of ovarian cancer categories and overall knowledge of ovarian cancer for participants	92	
4.9	Level knowledge on ovarian cancer among participants (N=366)	92	
4.10	Participants' beliefs about ovarian cancer screening, early detection and susceptibility	93	
4.11	Frequencies of attitude levels of participants (N=366)	93	
4.12	Factors associated with level of knowledge and attitude toward ovarian cancer among respondents	94	
4.13	Factors associated with level of attitude and attitude toward ovarian cancer among respondents	95	
4.14	Multivariate logistic regression analysis models towards ovarian cancer knowledge	96	
4.15	Multivariate logistic regression analysis models towards attitude toward ovarian cancer	97	
4.16	Total number of participants from each campus in Universiti Putra Malaysia at baseline	99	
4.17	Sociodemographic characteristics at baseline test (N=305), and comparison between the two groups	100	

4.18	Medical background of participants at baseline	101
4.19	Knowledge of ovarian cancer symptoms of participants at baseline	102
4.20	Knowledge of ovarian cancer' risk factors at baseline	103
4.21	Overall knowledge score of participants at baseline	104
4.22	Health believes related to ovarian cancer of participants in intervention and control groups at baseline	105
4.23	Frequency of endorsed and not endorsed barriers factor to seeing doctor by participants in the overall sample	106
4.24	Frequencies of endorsed barriers factor to seeing doctor by participants in intervention and control groups at baseline	106
4.25	Mean score of overall and 3 subtypes of perceived barriers to seeking help endorsed by participants at baseline	107
4.26	Association between perceived barriers to see doctor and sociodemographic and medical background of participants at baseline	108
4.27	Overall anticipated time for seeking-help to ovarian cancer symptoms for participants at baseline	110
4.28	Frequencies of anticipated help-seeking within ( $\leq$ median) of participants at baseline	111
4.29	Mean score of anticipated time for help-seeking to ovarian cancer symptoms of participants at baseline	112
4.30	Knowledge scores of ovarian cancer symptoms and anticipated help-seeking for ovarian cancer symptoms among participants at baseline	113
4.31	Association between anticipated help seeking and sociodemographic, medical background of participants at baseline	114
4.32	Correlation test analysis of associations between health beliefs related to ovarian cancer and anticipate help-seeking by overall sample participant at baseline	115
4.33	Comparison means scores of anticipated help-seeking between groups at different level of trials	116
4.34	Comparison of change in anticipated help-seeking mean scores of participants in control and intervention from baseline to 3 months after intervention	116
4.35	Pairwise comparison of change in anticipated help-seeking score within intervention group using GLM repeated measure	117
4.36	Comparison of changes in anticipated help-seeking scores within control group using GLM repeated measure	118
4.37	Changes in anticipated help-seeking score for participants in control and intervention groups across three level of trial	118
	assessments	
4.38	Pairwise comparison of anticipated time for help-seeking' scores at different levels of trials	119
4.39	Comparison mean scores of ovarian cancer knowledge between groups at different level of trial	120
4.40	Comparison of change in the mean scores of ovarian cancer knowledge of participants in control and intervention group at	121
4.41	baseline, immediately, and 3 months post- intervention Pairwise comparison of change in ovarian cancer knowledge score within intervention group using GLM repeated measure	121

<ul> <li>4.42 Comparison of changes in ovarian cancer knowledge scores within control group using GLM repeated measure</li> <li>4.43 Changes in mean score of ovarian cancer knowledge for participants in control and intervention groups across three level of trial assessments</li> <li>4.44 Pairwise comparison of ovarian cancer knowledge mean scores at different level of trial</li> <li>4.45 Comparison mean scores of perceived benifets between groups at different level of trial</li> <li>4.46 Comparison of changes in preceived benifets between groups at different level of trial</li> <li>4.47 Comparison of changes in preceived benefits mean scores within intervention group using GLM repeated measure</li> <li>4.48 Comparison of changes in preceived benefits mean scores within control group using GLM repeated measure</li> <li>4.49 Changes in the perceived benefits mean scores within control group using GLM repeated measure</li> <li>4.49 Changes in the perceived benefits mean scores at different level of trial</li> <li>4.50 Pairwise comparison of perceived benefits mean scores at different level of trial</li> <li>4.51 Comparison of change in preceived benefits mean scores at different level of trial</li> <li>4.52 Comparison of change in preceived susceptibility the between groups at three different level of trial</li> <li>4.51 Comparison of changes in perceived susceptibility within intervention group using GLM repeated measure</li> <li>4.52 Comparison of changes in perceived susceptibility within intervention group using GLM repeated measure</li> <li>4.53 Pairwise comparison of change in perceived susceptibility within intervention group using GLM repeated measure</li> <li>4.54 Comparison of change in perceived susceptibility within intervention group using GLM repeated measure</li> <li>4.55 Changes in mean scores of perceived susceptibility within intervention group using GLM repeated measure</li> <li>4.56 Comparison of change in perceived susceptibility within intervention group using GLM repeated measure</li> <li>4.</li></ul>				
<ul> <li>4.43 Changes in mean score of ovarian cancer knowledge for participants in control and intervention groups across three level of trial assessments</li> <li>4.44 Pairwise comparison of ovarian cancer knowledge mean scores at different level of trial</li> <li>4.45 Comparison of change in the mean scores of perceived benefits of participants in the control and intervention groups from baseline into 3 months post-intervention</li> <li>4.46 Comparison of change in perceived benefits mean scores within intervention group using GLM repeated measure</li> <li>4.47 Changes in the perceived benefits mean scores within control group using GLM repeated measure</li> <li>4.48 Comparison of perceived benefits mean scores within control group using GLM repeated measure</li> <li>4.49 Changes in the perceived benefits mean scores within control group using GLM repeated measure</li> <li>4.50 Pairwise comparison of perceived benefits mean scores at different level of trial assessments</li> <li>4.50 Pairwise comparison of perceived benefits mean scores at different level of trial assessments</li> <li>4.51 Comparison of change in the mean scores of perceived susceptibility of participants in control and intervention mediately, and 3 months after intervention measure</li> <li>4.52 Comparison of change in perceived susceptibility scores within intervention group using GLM repeated measure</li> <li>4.53 Pairwise comparison of change in perceived susceptibility scores within intervention group using GLM repeated measure</li> <li>4.54 Comparison of change in perceived susceptibility for participants in control and intervention</li> <li>4.55 Changes in mean scores of perceived confidence between groups at different level of trial</li> <li>4.56 Comparison of change in perceived susceptibility for participants in control and intervention group using GLM repeated measure</li> <li>4.56 Comparison of change in perceived confidence in symptoms detection score within intervention group using GLM repeated measure</li> <li>4.57 Comparison</li></ul>		4.42		122
different level of trials       125         4.45       Comparison mean scores of perceived benifets between groups at different level of trial       125         4.46       Comparison of change in the mean scores of perceived benefits of participants in the control and intervention groups from baseline into 3 months post-intervention       125         4.47       Comparison of changes in perceived benefits mean scores within intervention group using GLM repeated measure       126         4.48       Comparison of changes in perceived benefits mean scores within control group using GLM repeated measure       127         4.49       Changes in the perceived benefits mean scores of trial assessments       128         4.50       Pairwise comparison of perceived benefits mean scores at different level of trial assessments       129         4.51       Comparison of the mean scores of perceived susceptibility triate comparison of change in the mean scores of perceived susceptibility of participants in control and intervention from baseline into immediately, and 3 months after intervention       130         4.53       Pairwise comparison of change in perceived susceptibility scores within intervention group using GLM repeated measure       131         4.54       Comparison of changes in perceived susceptibility for participants in control and intervention from baseline into immediately, and 3 months after intervention       131         4.55       Changes in mean scores of perceived susceptibility scores within intervention group using GLM repeated measure		4.43	Changes in mean score of ovarian cancer knowledge for participants in control and intervention groups across three level	123
<ul> <li>different level of trial</li> <li>4.46 Comparison of change in the mean scores of perceived benefits of participants in the control and intervention groups from baseline into 3 months post-intervention</li> <li>4.47 Comparison of changes in perceived benefits mean scores within intervention group using GLM repeated measure</li> <li>4.48 Comparison of changes in perceived benefits mean scores within control group using GLM repeated measure</li> <li>4.49 Changes in the perceived benefits mean scores within control and the intervention groups across three levels of trial assessments</li> <li>4.50 Pairwise comparison of perceived benefits mean scores at different level of trial</li> <li>4.51 Comparison of the mean scores of perceived susceptibility 129 between groups at three different level of trial</li> <li>4.52 Comparison of change in the mean scores of perceived susceptibility of participants in control and intervention from baseline into immediately, and 3 months after intervention</li> <li>4.53 Pairwise comparison of change in perceived susceptibility corres within intervention group using GLM repeated measure</li> <li>4.54 Comparison of mean scores of perceived susceptibility for participants in control and intervention from baseline into immediately, and 3 months after intervention</li> <li>4.55 Changes in mean scores of perceived susceptibility for participants in control and intervention group sacross three levels of trial assessments</li> <li>4.56 Comparison of mean scores of perceived confidence between groups at different level of trial</li> <li>4.57 Comparison of change in perceived confidence in symptoms detection score within intervention group using GLM repeated measure</li> <li>4.58 Pairwise comparison of change in perceived confidence in symptoms detection score within intervention group using GLM repeated measure</li> <li>4.59 Comparison of changes in perceived confidence in symptoms detection score within intervention group using GLM repeated measure</li> <li>4.60 Changes in mean score</li></ul>		4.44	Pairwise comparison of ovarian cancer knowledge mean scores at	124
participants in the control and intervention groups from baseline into 3 months post-intervention       126         4.47       Comparison of changes in perceived benefits mean scores within intervention group using GLM repeated measure       126         4.48       Comparison of changes in perceived benefits mean scores within control group using GLM repeated measure       128         4.49       Changes in the perceived benefits scores for participants in the control and the intervention groups across three levels of trial assessments       127         4.50       Pairwise comparison of perceived benefits mean scores at different level of trial       129         4.51       Comparison of change in the mean scores of perceived susceptibility of participants in control and intervention mobaseline into immediately, and 3 months after intervention       130         4.52       Comparison of change in perceived susceptibility within intervention group using GLM repeated measure       131         4.54       Comparison of change in perceived susceptibility scores within control group using GLM repeated measure       132         4.55       Changes in mean scores of perceived confidence between groups at different level of trial       132         4.56       Comparison of change in perceived confidence between groups at different level of trial       134         6.56       Comparison of change in perceived confidence in symptoms detection score within intervention group using GLM repeated measure       135         4.58		4.45		125
intervention group using GLM repeated measure       128         4.48       Comparison of changes in perceived benefits mean scores within control group using GLM repeated measure       128         4.49       Changes in the perceived benefits scores for participants in the control and the intervention groups across three levels of trial assessments       129         4.50       Pairwise comparison of perceived benefits mean scores at different level of trial       129         4.51       Comparison of the mean scores of perceived susceptibility between groups at three different level of trial       129         4.52       Comparison of change in the mean scores of perceived susceptibility of participants in control and intervention from baseline into immediately, and 3 months after intervention       130         4.53       Pairwise comparison of change in perceived susceptibility scores within control group using GLM repeated measure       131         4.54       Comparison of mean scores of perceived susceptibility scores within control group using GLM repeated measure       132         4.55       Changes in mean scores of perceived confidence between groups at different level of trial       132         4.55       Comparison of mean scores of perceived confidence to measure       132         4.56       Comparison of change in the mean scores of perceived confidence to represent assessments       134         4.56       Comparison of change in perceived confidence in symptoms detection score within intervention		4.46	participants in the control and intervention groups from baseline	125
4.48       Comparison of changes in perceived benefits mean scores within control group using GLM repeated measure       128         4.49       Changes in the perceived benefits scores for participants in the control and the intervention groups across three levels of trial assessments       127         4.50       Pairwise comparison of perceived benefits mean scores at different level of trial       129         4.51       Comparison of the mean scores of perceived susceptibility between groups at three different level of trial       129         4.52       Comparison of change in the mean scores of perceived susceptibility of participants in control and intervention from baseline into immediately, and 3 months after intervention       131         4.53       Pairwise comparison of change in perceived susceptibility scores within control group using GLM repeated measure       131         4.55       Changes in mean scores of perceived susceptibility scores within control and intervention groups across three levels of trial assessments       132         4.56       Comparison of mean scores of perceived confidence between groups at different level frial       134         4.57       Comparison of change in herens scores of perceived confidence in symptoms detection score within intervention group using GLM repeated measure       135         4.58       Pairwise comparison of change in perceived confidence in symptoms detection scores within control group using GLM repeated measure       135         4.59       Comparison of changes in perceived conf		4.47	Comparison of changes in perceived benefits mean scores within	126
<ul> <li>control and the intervention groups across three levels of trial assessments</li> <li>4.50 Pairwise comparison of perceived benefits mean scores at different level of trial</li> <li>4.51 Comparison of the mean scores of perceived susceptibility 129 between groups at three different level of trial</li> <li>4.52 Comparison of change in the mean scores of perceived susceptibility of participants in control and intervention from baseline into immediately, and 3 months after intervention</li> <li>4.53 Pairwise comparison of change in perceived susceptibility within intervention group using GLM repeated measure</li> <li>4.54 Comparison of changes in perceived susceptibility scores within control group using GLM repeated measure</li> <li>4.55 Changes in mean scores of perceived confidence between groups at different level of trial assessments</li> <li>4.56 Comparison of mean scores of perceived confidence in groups at different level of trial assessments</li> <li>4.57 Comparison of change in perceived confidence in symptoms detection score within intervention group using GLM repeated measure</li> <li>4.58 Pairwise comparison of change in perceived confidence in symptoms detection score within intervention group using GLM repeated measure</li> <li>4.59 Comparison of changes in perceived confidence in symptoms detection scores within intervention group using GLM repeated measure</li> <li>4.60 Changes in mean scores of perceived confidence for participants in control and intervention group using GLM repeated measure</li> <li>4.60 Changes in mean scores of perceived confidence for participants in control and intervention group using GLM repeated measure</li> <li>4.60 Changes in mean scores of perceived confidence at 137 different levels of trial assessments</li> <li>4.61 Pairwise comparison of mean scores of perceived confidence at 137 different levels of trial assessments</li> </ul>		4.48	Comparison of changes in perceived benefits mean scores within	128
level of trial1294.51Comparison of the mean scores of perceived susceptibility between groups at three different level of trial1294.52Comparison of change in the mean scores of perceived susceptibility of participants in control and intervention from baseline into immediately, and 3 months after intervention1304.53Pairwise comparison of change in perceived susceptibility within intervention group using GLM repeated measure1314.54Comparison of changes in perceived susceptibility scores within control group using GLM repeated measure1314.55Changes in mean scores of perceived susceptibility for participants in control and intervention groups across three levels of trial assessments1324.56Comparison of mean scores of perceived confidence between groups at different level of trial1344.57Comparison of change in the mean scores of perceived confidence of participants in control and intervention from baseline into immediately, and 3 months after intervention mediately, and 3 months after intervention group using GLM repeated measure1354.58Pairwise comparison of change in perceived confidence in symptoms detection score within intervention group using GLM repeated measure1354.60Changes in mean scores of perceived confidence for participants in control and intervention group using GLM repeated measure1364.61Pairwise comparison of mean scores of perceived confidence at different levels of trial1374.62Comparison of mean scores of perceived confidence at atsessments136		4.49	control and the intervention groups across three levels of trial	127
between groups at three different level of trial1304.52Comparison of change in the mean scores of perceived susceptibility of participants in control and intervention from baseline into immediately, and 3 months after intervention 1311314.53Pairwise comparison of change in perceived susceptibility within intervention group using GLM repeated measure1314.54Comparison of changes in perceived susceptibility scores within control group using GLM repeated measure1324.55Changes in mean scores of perceived susceptibility for participants in control and intervention groups across three levels of trial assessments1324.56Comparison of mean scores of perceived confidence between groups at different level of trial1344.57Comparison of change in the mean scores of perceived confidence of participants in control and intervention from baseline into immediately, and 3 months after intervention1344.58Pairwise comparison of change in perceived confidence in symptoms detection score within intervention group using GLM repeated measure1354.59Comparison of changes in perceived confidence in symptoms detection scores within control group using GLM repeated measure1354.60Changes in mean scores of perceived confidence for participants in control and intervention groups across three levels of the trial assessments1364.61Pairwise comparison of mean scores of perceived confidence at different levels of trial1374.62Comparison of mean scores of perceived emotional barrier between138		4.50		129
<ul> <li>4.52 Comparison of change in the mean scores of perceived susceptibility of participants in control and intervention from baseline into immediately, and 3 months after intervention</li> <li>4.53 Pairwise comparison of change in perceived susceptibility within 131 intervention group using GLM repeated measure</li> <li>4.54 Comparison of changes in perceived susceptibility scores within control and intervention groups across three levels of trial assessments</li> <li>4.56 Comparison of change in the mean scores of perceived confidence between groups at different level of trial</li> <li>4.57 Comparison of change in perceived confidence between 132 groups at different level of trial</li> <li>4.58 Pairwise comparison of change in perceived confidence in symptoms detection score within intervention group using GLM repeated measure</li> <li>4.58 Pairwise comparison of change in perceived confidence in symptoms detection scores within intervention group using GLM repeated measure</li> <li>4.60 Changes in mean scores of perceived confidence for participants in control group using GLM repeated measure</li> <li>4.61 Pairwise comparison of mean scores of perceived confidence at different levels of trial</li> <li>4.62 Comparison mean scores of perceived emotional barrier between 138</li> </ul>		4.51		129
<ul> <li>4.53 Pairwise comparison of change in perceived susceptibility within intervention group using GLM repeated measure</li> <li>4.54 Comparison of changes in perceived susceptibility scores within control group using GLM repeated measure</li> <li>4.55 Changes in mean scores of perceived susceptibility for participants in control and intervention groups across three levels of trial assessments</li> <li>4.56 Comparison of mean scores of perceived confidence between groups at different level of trial</li> <li>4.57 Comparison of change in the mean scores of perceived confidence between of participants in control and intervention from baseline into immediately, and 3 months after intervention</li> <li>4.58 Pairwise comparison of change in perceived confidence in symptoms detection score within intervention group using GLM repeated measure</li> <li>4.59 Comparison of changes in perceived confidence in symptoms detection scores within control group using GLM repeated measure</li> <li>4.60 Changes in mean scores of perceived confidence for participants in control and intervention group using GLM repeated measure</li> <li>4.61 Pairwise comparison of mean scores of perceived confidence at different levels of trial</li> <li>4.62 Comparison mean scores of perceived emotional barrier between</li> </ul>		4.52	Comparison of change in the mean scores of perceived susceptibility of participants in control and intervention from	130
<ul> <li>4.54 Comparison of changes in perceived susceptibility scores within control group using GLM repeated measure</li> <li>4.55 Changes in mean scores of perceived susceptibility for participants in control and intervention groups across three levels of trial assessments</li> <li>4.56 Comparison of mean scores of perceived confidence between groups at different level of trial</li> <li>4.57 Comparison of change in the mean scores of perceived confidence of participants in control and intervention from baseline into immediately, and 3 months after intervention</li> <li>4.58 Pairwise comparison of change in perceived confidence in symptoms detection score within intervention group using GLM repeated measure</li> <li>4.59 Comparison of changes in perceived confidence in symptoms detection scores within control group using GLM repeated measure</li> <li>4.60 Changes in mean scores of perceived confidence for participants in control and intervention groups across three levels of the trial assessments</li> <li>4.61 Pairwise comparison of mean scores of perceived confidence at different levels of trial</li> <li>4.62 Comparison mean scores of perceived emotional barrier between</li> </ul>		4.53	Pairwise comparison of change in perceived susceptibility within	131
<ul> <li>4.55 Changes in mean scores of perceived susceptibility for participants in control and intervention groups across three levels of trial assessments</li> <li>4.56 Comparison of mean scores of perceived confidence between groups at different level of trial</li> <li>4.57 Comparison of change in the mean scores of perceived confidence of participants in control and intervention from baseline into immediately, and 3 months after intervention</li> <li>4.58 Pairwise comparison of change in perceived confidence in symptoms detection score within intervention group using GLM repeated measure</li> <li>4.59 Comparison of changes in perceived confidence in symptoms detection scores within control group using GLM repeated measure</li> <li>4.60 Changes in mean scores of perceived confidence for participants in control and intervention groups across three levels of the trial assessments</li> <li>4.61 Pairwise comparison of mean scores of perceived confidence at different levels of trial</li> <li>4.62 Comparison mean scores of perceived emotional barrier between 138</li> </ul>		4.54	Comparison of changes in perceived susceptibility scores within	131
<ul> <li>groups at different level of trial</li> <li>4.57 Comparison of change in the mean scores of perceived confidence of participants in control and intervention from baseline into immediately, and 3 months after intervention</li> <li>4.58 Pairwise comparison of change in perceived confidence in symptoms detection score within intervention group using GLM repeated measure</li> <li>4.59 Comparison of changes in perceived confidence in symptoms detection scores within control group using GLM repeated measure</li> <li>4.60 Changes in mean scores of perceived confidence for participants in control and intervention groups across three levels of the trial assessments</li> <li>4.61 Pairwise comparison of mean scores of perceived confidence at different levels of trial</li> <li>4.62 Comparison mean scores of perceived emotional barrier between 138</li> </ul>		4.55	Changes in mean scores of perceived susceptibility for participants in control and intervention groups across three levels of trial	132
<ul> <li>4.57 Comparison of change in the mean scores of perceived confidence of participants in control and intervention from baseline into immediately, and 3 months after intervention</li> <li>4.58 Pairwise comparison of change in perceived confidence in symptoms detection score within intervention group using GLM repeated measure</li> <li>4.59 Comparison of changes in perceived confidence in symptoms detection scores within control group using GLM repeated measure</li> <li>4.60 Changes in mean scores of perceived confidence for participants in control and intervention groups across three levels of the trial assessments</li> <li>4.61 Pairwise comparison of mean scores of perceived confidence at different levels of trial</li> <li>4.62 Comparison mean scores of perceived emotional barrier between 138</li> </ul>		4.56		132
<ul> <li>4.59 symptoms detection score within intervention group using GLM repeated measure</li> <li>4.59 Comparison of changes in perceived confidence in symptoms detection scores within control group using GLM repeated measure</li> <li>4.60 Changes in mean scores of perceived confidence for participants in control and intervention groups across three levels of the trial assessments</li> <li>4.61 Pairwise comparison of mean scores of perceived confidence at different levels of trial</li> <li>4.62 Comparison mean scores of perceived emotional barrier between 138</li> </ul>		4.57	Comparison of change in the mean scores of perceived confidence of participants in control and intervention from baseline into	134
<ul> <li>4.59 Comparison of changes in perceived confidence in symptoms detection scores within control group using GLM repeated measure</li> <li>4.60 Changes in mean scores of perceived confidence for participants in control and intervention groups across three levels of the trial assessments</li> <li>4.61 Pairwise comparison of mean scores of perceived confidence at different levels of trial</li> <li>4.62 Comparison mean scores of perceived emotional barrier between 138</li> </ul>		4.58	Pairwise comparison of change in perceived confidence in symptoms detection score within intervention group using GLM	135
<ul> <li>4.60 Changes in mean scores of perceived confidence for participants 136 in control and intervention groups across three levels of the trial assessments</li> <li>4.61 Pairwise comparison of mean scores of perceived confidence at 137 different levels of trial</li> <li>4.62 Comparison mean scores of perceived emotional barrier between 138</li> </ul>		4.59	Comparison of changes in perceived confidence in symptoms detection scores within control group using GLM repeated	135
<ul> <li>4.61 Pairwise comparison of mean scores of perceived confidence at 137 different levels of trial</li> <li>4.62 Comparison mean scores of perceived emotional barrier between 138</li> </ul>	$(\mathbf{G})$	4.60	Changes in mean scores of perceived confidence for participants in control and intervention groups across three levels of the trial	136
4.62 Comparison mean scores of perceived emotional barrier between 138		4.61	Pairwise comparison of mean scores of perceived confidence at	137
		4.62		138

4.63	Comparison of change in the mean scores of perceived emotional barrier of participants in control and intervention from baseline into 2 months post intervention	138
4.64	into 3 months post-intervention Pairwise comparison of change in perceived emotional barriers score within intervention group using GLM repeated measure	139
4.65	Comparison of changes in perceived emotional barriers scores within control group using GLM repeated measure	140
4.66	Changes of mean scores of perceived emotional barrier for participants in control and intervention groups across three levels of trial assessments	140
4.67	Pairwise comparison of mean score of perceived emotional barriers at different level of trial	142
4.68	Comparison mean scores of perceived practical barrier between groups at different level of trial	142
4.69	Comparison of change in the mean scores of perceived practical barrier of participants in control and intervention from baseline into 3 months after intervention	143
4.70	Pairwise comparison of change in perceived practical barrier score within intervention group using GLM repeated measure	144
4.71	Comparison of changes in perceived practical barrier scores within control group using GLM repeated measure	144
4.72	Changes in mean scores of perceived practical barrier for participants in control and intervention groups cross three levels of trial assessments	145
4.73	Pairwise comparison of mean score of perceived practical barrier at different level of trial	146
4.74	Comparison of the mean scores of perceived service barrier between groups at different level of trial	147
4.75	Comparison of change in the mean scores of perceived service barrier of participants in control and intervention from baseline into immediately, and 3 months after intervention	147
4.76	Pairwise comparison of change in perceived service barrier mean score within intervention group using GLM repeated measure	148
4.77	Changes of mean scores of perceived survice barrier for participants in control and intervention groups across thre levels of trial assessments	149

# LIST OF FIGURES

Figure		Page		
2.1	Annual mortality rate (per 100, 000 people) of ovarian cancer in	14		
	Malaysia from 1990 to 2013			
2.2	The General Model of Total Patient Delay	32		
2.3	.3 Conceptual framework of the interrelation of HBM's concepts an			
	their relation to behavior change			
2.4	Conceptual framework of study based on Health Belief Model 5'			
3.1	Flow chart illustrates the three phases of the study 58			
3.2	North campus of UPM 77			
3.3	South campus of UPM	73		
3.4	Flow chart on study design and outcome evaluation	76		
3.5	Consort flow diagram of the study	78		
4.1	Flow chart of recruitment and retentions of the participants during	98		
	study's time			
4.2	Mean score of Anticipated Help-seeking Between Group Overtime	119		
4.3	Mean Score of Ovarian Cancer Knowledge Between Groups	123		
	Overtime			
4.4	Mean scores of Perceived Benefits Between Groups Over Time	128		
4.5	Mean Scores of Perceived Susceptibility Between Groups Over	132		
	Time			
4.6	Mean scores of Perceived Confidence Between Groups Over Time	136		
4.7	Mean Scores of Perceived Emotional Barrier Between Group	141		
	Overtime			
4.8	Mean scores of Perceived Practical Between Groups Over Time	145		
4.9	Mean Scores of Perceived Service Barrier Between Groups Over	149		
	Time			

 $\int$ 

# LIST OF ABBREVIATIONS

	OR	Odds Ratio
	aOR	Adjusted Odds Ratio
	PPV	Positive Predictive Value
	HRT	Hormonal Replacement Therapy
	ССР	Contraceptive Pills
	SES	Socio-Economic Status
	RR	Rate Ratio
	HR	Hazard Risk
	SI	Symptoms Index
	MET	Metabolic Equivalent Tasks
	BMI	Body Mass Index
	UPM	University Putra Malaysia
	CA 125	Cancer Antigen 125
	САМ	Cancer Awareness Measure
	ABC	Awareness and Beliefs about Cancer Measure
	ABC-O	Awareness and Belief about Cancer-Ovarian Measure
	Ovarian CAM	Ovarian-Cancer Awareness Measure
	НВМ	Health Belief Model
	BRCA	Breast cancer suppressive gene
	GLM	General Linear Model
$\bigcirc$	ANOVA	Analysis of Variance
4		



#### **CHAPTER 1**

#### INTRODUCTION

#### 1.1 Background

Ovarian cancer (OC) ranks among the top ten diagnosed cancer in most countries (Ferlay, Héry, Autier & Sankaranarayanan, 2010). It is the seventh most common cancer world wide (Stewart, 2012). According to Ferlay et al. (2010), a total of 224,747 new cases of ovarian cancer were reported worldwide in 2008, 99,521 cases of them diagnosed in more developed countries, and 125,226 in less developed countries. Ovarian cancer is the second common gynecological cancer followed by uterine and cervical cancer in developing countries (Iyoke & Ugwu, 2013).

Malaysian statistics show that cancer of the ovary was the fourth most common cancer among women in Peninsular Malaysia (National Cancer Registry, Malaysia, 2011). It composed of 6.1% of total female cancer and the crude incidence rate of 5.9 per 100,000 populations (National Cancer Registry, Malaysia, 2011), and crude death rate of 4.5 per 100,000 (Razi et al., 2016). The incidence rate of ovarian cancer in Malaysia represent the seventh highest incidence among Asian countries while the crude mortality rate is the eighth highest among them (Razi et al., 2016).

Despite advances in chemotherapy and surgery, ovarian cancer is a particularly deadly gynecological malignancy worldwide (Lutz et al., 2011). It ranks among the top five most fatal malignancies in most countries (Ferlay et al., 2010). Ovarian cancer has a high proportion of deaths compared to the number of diagnosed cases. On a worldwide basis, 225,000 cases of ovarian cancer were diagnosed in 2005, with 140,100 deaths (Ferlay et al., 2010; Sankarayanan & Ferlay, 2006).

Ovarian cancer is an insidious disease, and prognoses of cases are closely related to the tumor stage at the time of diagnosis. It has highly curable rate when it is diagnosed at early stages (stage I, and II) (Jayson, Kohn, Kitchener & Ledermann, 2014). The 5-years survival rate of diagnosed cases at stage I and stage II is as high as 80.6 %. However, it is only 11.2-33.3 % 5-year survival rate when the disease has spread outside the pelvis (stage III – IV) (George et al., 2013). However, most of the ovarian cancer cases (70% to 75%) have been diagnosed at stages III-IV world wide (Jayson et al., 2014). Hence, many screening strategies have been developed to detect ovarian cancer early to improve the 5-years mortality rate.

Considerable attention has been made to explore the efficacy of current ovarian cancer screening methods in the reduction of mortality. However, this efficacy has not been established yet (Menon, Griffin, & Gentry-Maharaj, 2014). Current ovarian cancer screening that is based on transvaginal ultrasound exam or CA-125 blood test do not have enough level of sensitivity and specificity (Drescher et al., 2012; Van Der Velde et

al., 2009; Kobayashi et al., 2008). Indeed, they do not reduce the mortality rate of ovarian cancer as shown in a quite recent result of the biggest trial (United Kingdom Collaborative Trial of Ovarian Cancer Screening) (UKCTOCS) that address effect of different screening strategies on ovarian cancer mortality rate (Jacobs et al., 2016).

For several years significant efforts have been devoted to the study of ovarian cancer early symptoms. These studies refute the old misconception that early stages of ovarian cancer have no warning signs and symptoms (Hamilton et al., 2009; Goff, Mandel, Melancon & Muntz, 2004). Most of the early ovarian cancer symptoms mimic the symptoms of common disorders or benign conditions such as irritable bowel syndrome, gastritis, dietary problems, urinary tract infection, stress or even depression (Cooper, Polonec, Stewart & Gelb, 2012). Indeed, these signs and symptoms include mainly, bloating, increase the size of the abdomen, pelvic or abdominal pain, early satiety, change in bowel habits, and frequent urination (Hamilton, Peters, Bankhead, & Sharp, 2009; Bankhead et al., 2008; Goff et al., 2004). Progression of medical research in this field was large enough to develop the Ovarian Cancer Symptoms Index (Goff et al., 2007). The sensitivity of this cost-free screening method is 56.7% for early stages and 79.5% for late stages. The specificity ranged from 86% to 90% (Goff et al., 2007). Given that single effective ovarian cancer screening in the general population is not available yet and development of symptoms index, early detection of ovarian cancer reliant upon women recognition of the symptoms and seek medical help has been gaining importance in recent years.

Even though the majority of women with ovarian cancer experienced symptoms at early stages, they did not seek medical help after the onset (Forbes, Warburton, Richards & Ramirez, 2014; Simon et al., 2010; Macleod, Mitchell, Burgess, Macdonald & Ramirez, 2009). The most important factor associated with the extended period of symptomatic presentation is those that related to women's health care-seeking behaviors (Yawn et al., 2004), i.e., delay presentation to medical care or lack of completion to recommended test. Patient - related delay among women with ovarian cancer is well documented by several publications that used a broad range of research methods (Cooper, Gelb, Trivers & Stewart, 2016; Brain et al., 2014; Low et al., 2013; Morris, Sands & Smith, 2010; Evan et al., 2007).

Many studies found that positive early detection behaviors such as help-seeking behavior or intending help-seeking behavior can lead to early diagnoses if the person has enough awareness about warning signs of disease and overcome the practical and perceived barriers (Rahaei, Ghofranipour, Morowatisharifabad & Mohammadi, 2015; de Nooijer, Lechner & de Vries, 2002). Unfortunately, the majority of women have a low level of awareness related to early signs and symptoms of ovarian cancer, and these are the reasons behind their delay to seek medical help (Ferrell, Smith, Cullinane & Melancon, 2003; Goff Goff, Mandel, Muntz & Melancon, 2000). Intention to seeking help for most ovarian cancer symptoms was low (Cooper et al., 2016; Brain et al., 2014), because they did not recognize symptoms as particularly serious (Evan et al., 2007) which may negatively affect the time needed to diagnosed cases of ovarian cancer.

Previous studies conducted in Malaysia shows a low level of ovarian cancer knowledge among Malaysian women (AL-Naggar, Osman, Bobrysher, & Abdul Kadir, 2013) and risk factors (Keng, Bainun, Wahab, Chiu & Yusuf, 2015), and negative belief and perceived barriers to seek cancer screening services (Farooqui et al., 2013; Wong, Wong, Low, Khoo & Shuib, 2009) that affects help-seeking behavior among Malaysian women.

It is clear that educating women to increase their level of knowledge about possible early symptoms of ovarian cancer might have a positive impact on the early detection of ovarian cancer and thus enhance survival. Efforts of ovarian cancer health education programs and campaigns are needed to highlight the nature of ovarian cancer symptoms; benefits of early detection of this disease and it should focus on the usage of symptoms based ovarian cancer screening tool. The awareness is definitely will increase the proportion of women who present early to the clinic.

#### 1.2 Problem Statement

The poor survival rate of ovarian cancer cases is currently a problem internationally. In Malaysia, medical statistics showed highest death-to-incidence ratio. Ovarian cancer in Malaysia kills about 4.5 per 100,000 women (Razi et al., 2012) while it is affecting 5.9 per 100.000 women/year (National Cancer Registry, Malaysia, 2011). It has earned itself the title as the deadliest of all gynecological cancer, and that results from it being often diagnosed at late stages of disease (Ferlay et al., 2010).

Early diagnosis of ovarian cancer is important because of the established association between stage when ovarian cancer is diagnosed and the 5- years' survival rate (Green, 2016; Su, Graybill, & Zhu, 2013). Ovarian cancer diagnosed at earlier stages (stage I, II) have higher 5-year survival rate than cases diagnosed in late stages (III, IV). However, the majority of women with ovarian cancer are diagnosed at advanced stages (III, and IV) (Su et al., 2013). In Malaysia, more than half of cases diagnosed at late stages (III, IV) (National Cancer Registry, Malaysia, 2011). Therefore, early detection is critical and should be well addressed to improve ovarian cancer outcomes.

Early diagnosis of ovarian cancer is the biggest challenge, and its prognosis has remained poor without any change in the overall mortality rate. That is a result of many causes. First, failure of medical science to find practical screening tool that can detect ovarian cancer among women in the general population. Second, the vagueness of symptoms (Jayde, White & Blomfield, 2010) which are unrecognizable by the majority of women resulting them to seek medical help at late stages. Therefore, it is typically presented at advanced stages when prognosis is poor.

Unfortunately, studies about ovarian cancer awareness that target different populations of women repeatedly have displayed a non-profound knowledge regarding symptoms and risk factors of ovarian cancer (Brain et al., 2014; Fallowfield et al., 2010; Jones et al., 2010; Lockwood-Rayerman et al., 2009). There is a poor public knowledge compared

to breast cancer (Carter, DiFeo, Bogie, Zhang & Sun, 2014). In Malaysia, there is a critical ovarian cancer knowledge gap among women in the general population (AL-Naggar et al., 2013). Therefore, enhancing public awareness of the potential early symptoms must be the priority toward expediting diagnosis, which can be accomplished by Improve symptoms recognition and enhance early detection of ovarian cancer via selectively examining women who present with particular symptoms' cluster suggestive ovarian cancer (Hamilton et al., 2009; Bankhead et al., 2008; Goff et al., 2004).

Early detection of ovarian cancer can begin with women reports symptoms to health care provider. Prolong of time that women need it to report these symptoms, can be affected by many factors. For example, lack of cancer symptoms knowledge, young women, unretired women, ethnic differences, education level, unconfidence in symptoms detection, and perceived barriers (Cooper et al., 2016; Brain et al., 2014; Low et al., 2013). On the whole, as soon as women recognized and report her symptoms to health care provider, the time need for diagnoses will be shorter. That is to say, the timing of help-seeking for potential cancer symptoms is a potentially modifiable approach to improving early diagnosis.

Consequently, identification of knowledge's gaps related to ovarian cancer and apply an evidence-based intervention to minimize it and promote help-seeking will enhance the early symptomatic presentation of patients and improve survival. Women should be informed about the cluster of symptoms and signs that could indicate the presence of ovarian cancer, and enable them to be their health care advocates (Jayade et al., 2010).

It is apparent from the above that demonstrate a need for more compelling educations efforts to raise awareness related to ovarian cancer symptoms and refute misconceptions surroundings this disease. Equally important, educational intervention is required to overcome the barriers to a timely appropriated symptomatic presentation, and improve women confidence in their ability to recognize and act upon these symptoms. To our knowledge, this intervention study is unique in attempting to increase ovarian cancer awareness and promote the timely help-seeking for ovarian cancer symptoms among Malaysian population.

#### 1.3 Significance of the Study

Measuring of the actual time needed to seek care for the real ovarian cancer symptoms is difficult, either retrospective or prospective. However, analysis of meta-analysis indicated that intention behavior explained 28% of the variances in future behavior (Sheeran, 2002). Thus, the time for seeking medical help for possible symptoms was measured which might reflect the actual behavior. This study is among the few studies that attempted to test the effectiveness of an educational intervention on timely seeking help for hypothetical ovarian cancer symptoms.

The result of this study is useful in the Malaysian's public health field as the population under study is Malaysian female working women. This study explored knowledge of Malaysian women on ovarian cancer and their anticipated time to seek help for symptoms associated with ovarian cancer as well as their perceived barriers to request help for these symptoms. In fact, the implemented intervention was an attempt to overcome the barriers of the timely symptomatic presentation via improving participants' understanding of early symptoms and signs associated with ovarian cancer, the evaluating of early presentation of cases, and enhancing women's confidence and personal abilities to recognize and act upon ovarian symptoms.

Finding of this study will play a significant role in empower university-community engagement-transfer evidence-based knowledge on ovarian cancer symptoms, screening methods and intention-behavior related to seek medical help for its symptoms. Besides, study finding is useful to help the policy maker to understand more about the real and current situation of the target population, and use a relevant primary data which are necessary for any well-planned health program and efficient strategies that aimed to improve ovarian cancer long term survival.

Identifying and documenting the levels of ovarian cancer awareness, anticipated time to seek medical help and perceived barriers to see a doctor among Malaysian population provide an opportunity for national and international comparative purposes. Moreover, it offered a chance to test the Health Belief Model (HBM) theory in term of modifying health care seeking behavior among Malaysian working women. The result of this study can provide a substantial empirical support of the model and can add more evidence on the model's performance.

#### **1.4 Research Questions**

#### 1.4.1 Research Questions of Phase I (Cross sectional study)

- i. What is the level of ovarian cancer knowledge among female non-academic staff on ovarian cancer symptoms, risk factors, and early detection and screening?
- ii. What is the attitude held by female non-academic staff towards ovarian cancer screening and early detection?
- iii. What are the best predictors for knowledge and attitude related to ovarian cancer among female non-academic staff in UPM?
- iv. What is the source of information related to ovarian cancer among female nonacademic staff in UPM?

#### 1.4.2 Research Question of Phase III

What is the effect of the intervention on the anticipated help-seeking, knowledge, health beliefs related to ovarian cancer among female non-academic staff in UPM at baseline assessment?

## 1.5 Research Objectives

#### 1.5.1 General Objectives

To develop, implement, and evaluate the effectiveness of electronic-based health education intervention on the anticipated help-seeking, knowledge, and health beliefs related to ovarian cancer among female non-academic staff in UPM.

#### 1.5.2 Specific Objectives:

- i. To determine the level of ovarian cancer knowledge among female nonacademic staff in UPM.
- ii. To determine the level of attitude related to ovarian cancer early detection and screening among female non-academic staff in UPM.
- iii. To identify sources of ovarian cancer information among participants.
- iv. To determine the association between the sociodemographic factors, personal family medical background with the ovarian cancer knowledge and attitude among female non-academic staff of UPM.
- v. To determine the best predictors of a low level of knowledge and attitude towards OC.
- vi. To develop ovarian cancer health education module that can improve anticipated help-seeking, knowledge, and beliefs related to ovarian cancer among female non-academic staff in UPM.
- vii. To determine the levels of anticipated help-seeking, knowledge, health beliefs, related to ovarian cancer among female non-academic staff at baseline in both groups at baseline.
- viii. To compare the mean scores of anticipated help-seeking, knowledge, health beliefs related to ovarian cancer between control and intervention groups at immediately, and 3-months after intervention.
- ix. To compare the mean scores of anticipated help-seeking, knowledge, health beliefs related to ovarian cancer between baseline and post intervention assessment within each group.

## 1.6 Research Hypotheses

- I. Sociodemographic factors, personal and family medical background have a significant associations with the ovarian cancer knowledge and attitude among female non-academic staff in UPM.
- II. There are significant differences between control and intervention groups for anticipated help-seeking, knowledge, health beliefs related to ovarian cancer at immediately, and 3-months after intervention.
- III. There are significant different between baseline and post intervention assessment of the mean score for anticipated help-seeking, knowledge, health beliefs related to ovarian cancer among intervention group.

### 1.7 Operational Definitions of Study Variables

#### 1.7.1 Dependent Variable

## I. Primary Dependent Variable

#### Anticipated help-seeking for symptoms associated with ovarian cancer.

It is a variable which describe immediate medical help seeking for ovarian cancer symptoms in a hypothesized way. It is the primary outcome and measured by one item questions: How soon would you contact your doctor to make an appointment to discuss this symptom? Intended time for each symptom was assessed separately. Ten options were provided to answer this question: (1-3 days, 4-6 days, one week, two weeks, one month, six weeks, three months, six months, 12 months, never). Then the options was dichotomized into help-seeking by the median-chosen cutoff point or earlier (prompt help-seeking), and help-seeking longer than the median score (delay seeking help). Summation help-seeking score which ranges from 0 to 10, with higher score indicate prompted help-seeking for most of the symptoms.

#### II. Secondary Dependent Variable

#### Knowledge of Ovarian Cancer

In this study, knowledge of ovarian cancer was defined as the ability of participants to recognize possible ovarian cancer warning signs and symptoms as well as its predisposing factors. It was assessed by measuring the proportion of right knowledge that participant has. Knowledge of ovarian cancer in this study was the secondary dependent variable and affect the anticipated help-seeking for ovarian cancer symptoms.

#### Health Beliefs Retread to Ovarian Cancer

Ovarian cancer health-related beliefs are used to describe and monitor participant's beliefs and attitude toward four constructs. Health beliefs in this study were a secondary outcome that may affect participant' decision and ability to seek medical care for their symptoms. Health beliefs related to ovarian cancers were composed of four constructs which include:

a. Perceived benefits of early presentation

Definition of perceived benefits of early presentation in this study is the participants' beliefs about the efficacy of the advised action (seeking medical care soon for symptoms associated with ovarian cancer) to reduce the risk of the seriousness of the impact. It was measured by the proportion of participant' agreement with five positive statement related to the benefits of early presentation and diagnosis of ovarian cancer.

b. Perceived susceptibility to ovarian cancer.

In this study, perceived susceptibility to ovarian cancer was defined as participants' beliefs about their possibilities of getting ovarian cancer in future. Perceived susceptibility used 5-point scales (from strongly disagree to strongly agree). It was assessed by proportion of participants who agree or strongly agree with four items described the likelihood of developing ovarian cancer.

c. Perceived confidence in symptoms detection

In this study, perceived confidence in symptom detection was defined as participants' self-efficacy to their abilities to notice symptoms of ovarian cancer. It was assessed by proportion of participants on how confident or very confidence to detect ovarian cancer symptoms as they responded to one item question (How confident or not, are you that you would notice a symptom of ovarian cancer?).

d. Perceived barriers to presentation

The perceived barrier to the presentation was defined in this study as participants' opinion about tangible, and psychological costs to see a doctor (medical health provider) as a responded to ovarian cancer symptoms. Three barriers included in this study (Emotional barrier; Practical barrier, and Service barrier). Each barrier was assessed by proportion of participant who endorsed this barrier.

# 1.7.2 Independent Variables

# I. Health Education Intervention

Health education intervention variable: It is a health education program designed to provide a health information related to ovarian cancer. Namely: early ovarian symptoms, predisposing factors, survival rate, stages, prognoses, screening methods, current standard of diagnosis and treatment. All this information is provided to participants during intervention phase in a particular package used to close the knowledge gap between the up to date existing knowledge and that which is known and believes by participants.

Education package is composed of:

- 1. Six minutes long video with cartoon intimated design with Bahasa Malayu language.
- 2. Tailored printed material (leaflet + copy of ovarian cancer symptoms checklist diary) have been written in Bahasa Malayu language.

(Video was delivered to participants via electronic based methods, e.g., WhatsApp, and Emails)

# II. Socio-demographic Characteristics Variable

Socio-demographic variables: it is information about the following characteristics (age, race, religious, marital status, the level of education, and family monthly income.

#### III. Personal and family medical background variable

Family and personal medical background variables: it is information about the personal history of using contraceptive pills and hormonal replacement therapy and their duration, Past or present history of ovarian or breast cancer among first or second relatives as well as information about the personal history of breast cancer.

#### 1.8 Definition of Terms

#### **Ovarian cancer**

It is a type of malignant tumor that begins at ovaries.

#### Early detection of ovarian cancer

It is the diagnoses of ovarian cancer in stage I or stage II.

# 5 - Years survival rate

It is the percentage of ovarian cancer patients who live at least five years after cancer diagnosed.

#### **Ovarian cancer symptoms**

It is the abnormal sensation or conditions that women with ovarian cancer can notice. Symptoms described in this study are the symptoms reported by (Goff et al., 2007). They include:

- a. Persisted abdominal/pelvic pain.
- b. Feeling full quickly.
- c. Urgency or frequency of urination.
- d. Unexplained change in bowel habits.
- e. Increased abdominal size.
- f. Weight loss/gain.
- g. Back pain.
- h. Unusual fatigue.

#### Ovarian cancer' symptoms checklist screening tool

It is a personal instrument in the form of the diary. Composed of a list of symptoms that might be caused by early stages of ovarian cancer, along with duration and frequency.

#### Anticipated time for help-seeking for ovarian cancer symptoms.

It is the duration of predetermined time from ovarian cancer symptoms onset to the time when women seek medical care for their symptom (s).

## **Electronic- based intervention**

It is the intervention that is delivered to target group mainly through the WhatsApps and E-mail that are easily used by daily personal electronic gadgets such as hand phone or tablets

# Female non-academic staff

In this study, the female non-academic staff is the woman whose work is administrative or technical, or professional or management officers (support staff) and met all inclusion and exclusion criteria.

# **Public university**

It's a university that predominantly funded by the Malaysian government and managed as self-managed institutions.

# A randomized controlled trial

It's a quantitative study in which participants were allocated by chance either to group where participants received education intervention or to group where no intervention, and they received the education intervention at the end of the study. With, measured and compared the outcomes after the participants in intervention group received the intervention



## REFERENCES

- Abdullahi, A., Hassan, A., Kadarman, N., Saleh, A., Baraya, Y. U. S. A., & Lua, P. L. (2016). Food safety knowledge, attitude, and practice toward compliance with abattoir laws among the abattoir workers in Malaysia. *International Journal of General Medicine*, 9, 79.
- Abidin, A. A. Z., Razak, W. D. A. W. A., Asri, A. A. A., Latiff, L. A., & Akhtari-Zavare, M. (2015). Factors associated with knowledge regarding ovarian cancer and ovarian cancer screening among female staff in Universiti Putra Malaysia. *International Journal of Public Health and Clinical Sciences*, 2(4), 63-74.
- Adeyemil, A.S., Afolabi, A.F., & Adedeji, O.A. (2015). Ovarian cancer symptom awareness and its response among female health workers. *British Journal of Medicine & Medical Research*, 5(8), 978-986, DOI: 10.9734/BJMMR/2015/13354
- Adonakis, G. L., Paraskevaidis, E., Tsiga, S., Seferiadis, K., & Lolis, D. E. (1996). A combined approach for the early detection of ovarian cancer in asymptomatic women. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 65(2), 221-225.
- Akhtari- Zavare, M., A Lattif, L., Juni, M. H., Md Said, S., & Ismail, I. Z. (2015). Predictors affecting breast self- examination practice among undergraduate female students in Klang Valley, Malaysia. *Journal of Obstetrics and Gynaecology Research*, 41(12), 1982-1987.
- Al-Azri, M., Al-Hamedi, I., Al-Awisi, H., Al-Hinai, M., & Davidson, R. (2015). Public awareness of warning signs and symptoms of cancer in Oman: a communitybased survey of adults. Asian Pac J Cancer Prev, 16(7), 2731-2737.
- Allgar, V. L., & Neal, R. D. (2005). Delays in the diagnosis of six cancers: analysis of data from the National Survey of NHS Patients: Cancer. *British Journal of Cancer*, 92(11), 1959.
- AL-Naggar, R.A., Osman, M.T., Bobrysher, Y.V., Abdul Kadir, S.Y. (2013). Ovarian cancer: knowledge of risk factors and symptoms among working Malaysian women. *Middle-east Journal of Scientific Reseach* 14 (14):549-553, DOI 10.5829/idosi.mejsr.2013.14.4.7365
- American Cancer Society, ovarian cancer: causes, risk factors, and prevention.retrieved October, 2015, from <u>https://www.cancer.org/cancer/ovarian-cancer/causes-risks-prevention/risk-factors.html</u>
- Andersen, B. L., Cacioppo, J. T., & Roberts, D. C. (1995). Delay in seeking a cancer diagnosis: delay stages and psychophysiological comparison processes. *British Journal of Social Psychology*, *34*(1), 33-52.
- Anderson, J. P., Ross, J. A., & Folsom, A. R. (2004). Anthropometric variables, physical activity, and incidence of ovarian cancer. *Cancer*, 100(7), 1515-1521.
- Andersen, M. R., Peacock, S., Nelson, J., Wilson, S., McIntosh, M., Drescher, C., & Urban, N. (2002). Worry about ovarian cancer risk and use of ovarian cancer screening by women at risk for ovarian cancer. *Gynecologic Oncology*, 85(1), 3-8.
- Andersen, M. R., Drescher, C. W., Zheng, Y., Bowen, D. J., Wilson, S., Young, A., ... & Urban, N. (2007). Changes in cancer worry associated with participation in ovarian cancer screening. *Psycho-Oncology*, 16(9), 814-820. DOI: 10.1002/pon.1151

- Andersen, R.S., Paarup, B., Vedsted, P., Bro, F., & Soendergaard, J. (2010). Containment as an analytical framework for understanding patient delay: A qualitative study of cancer patients' symptoms interpretation processes. *So Sci Med*, 71(2), 378-385
- Andersen, R.S., Vedsted, P., Olesen, F., Bro, F., & Søndergaard, J. (2009). Patient delay in cancer studies: a discussion of methods and measures. *BMC Health Serv Res*, 9 (1),189. doi: 10.1186/1472-6963-9-189.
- Arukesamy, K. (2017). National study on ovarian cancer hopes to increase awareness of genetic testing. Retrieved 21July, from <u>http://www.thesundaily.my/news/2017/05/08/national-study-ovarian-cancer-hopes-increase-awareness-genetic-testing</u>
- Attanucci, C. A., Ball, H. G., Zweizig, S. L., & Chen, A. H. (2004). Differences in symptoms between patients with benign and malignant ovarian neoplasms. *American Journal of Obstetrics and Gynecology*, 190(5), 1435-1437.
- Austoker, J., Bankhead, C., Forbes, L. J., Atkins, L., Martin, F., Robb, K., ... & Ramirez, A. J. (2009). Interventions to promote cancer awareness and early presentation: systematic review. *British Journal of Cancer*, 101(Suppl 2), S31-S39.
- Bankhead, C. R., Collins, C., Stokes- Lampard, H., Rose, P., Wilson, S., Clements, A., ... & Austoker, J. (2008). Identifying symptoms of ovarian cancer: a qualitative and quantitative study. *BJOG: An International Journal of Obstetrics & Gynaecology*, 115(8), 1008-1014. doi 10.1111/j.1471-0528.2008.01772.x
- Bankhead, C.R, Kehoe, S.T, Austoker, J. (2005). Symptoms associated with diagnosis of ovarian cancer: a systematic review. *BJOG*,112(7), 857-65.
- Bekar, M., Guler, H., Evcili, F., Demirel, G., & Duran, O. (2013). Determining the knowledge of women and their attitudes regarding gynecological cancer prevention. Asian Pacific Journal of Cancer Prevention, 14(10), 6055-6059.
- Bluman, L.G., Rimen, B.K., Bery, D.A., et al. (1999). Attitude, knowledge, and risk perception of women with breast cancer and/or ovarian cancer considering testing for BRCA1 and BRCA2. *J clin oncol*,17,1040-1046.
- Booth, M., Beral, V., Smith, P.(1989). Risk factors for ovarian cancer: a case control study. *Br.J.Cancer*, 60, 592-598.
- Bosetti, C., Negri, E., Franceschi, S., Pelucchi, C., Talamini, R., Montella, M., ... & La Vecchia, C. (2001). Diet and ovarian cancer risk: a case- control study in Italy. *International Journal of Cancer*, 93(6), 911-915.
- Boxell, E. M., Smith, S. G., Morris, M., Kummer, S., Rowlands, G., Waller, J., ... & Simon, A. E. (2012). Increasing awareness of gynecological cancer symptoms and reducing barriers to medical help seeking: does health literacy play a role?. *Journal of Health Communication*, *17*(sup3), 265-279.
- Brain, K. E., Smits, S., Simon, A. E., Forbes, L. J., Roberts, C., Robbé, I. J., ... & Hanson, J. (2014). Ovarian cancer symptom awareness and anticipated delayed presentation in a population sample. *BMC Cancer*, 14(1), 171. doi: 10.1186/1471-2407-14-17.
- Buys, S. S., Partridge, E., Black, A., Johnson, C. C., Lamerato, L., Isaacs, C., ... & Crawford, E. D. (2011). Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. *Jama*, 305(22), 2295-2303. Doi:10.1001/jama.2011.766.
- Buys, S. S., Partridge, E., Greene, M. H., Prorok, P. C., Reding, D., Riley, T. L., ... & Izmirlian, G. (2005). Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the

initial screen of a randomized trial. *American Journal of Obstetrics and Gynecology*, *193*(5), 1630-1639.

- Cancer Stat Facts, Ovarian Cancer, SEER, National Cancer Institute. Retrieved 12 April, from https://seer.cancer.gov/statfacts/html/ovary.html
- Carter, R. R., DiFeo, A., Bogie, K., Zhang, G.-Q., & Sun, J. (2014). Crowdsourcing awareness: exploration of the ovarian cancer knowledge gap through Amazon Mechanical Turk. *PloS One*, *9*(1), e85508.
- Chambers, S. K., & Hess, L. M. (2008). Ovarian cancer prevention. In *Fundamentals of Cancer Prevention* (pp. 447-473). Springer Berlin Heidelberg.
- Chan, Y. H. (2003). Biostatistics 104: correlational analysis. *Singapore Med J*, 44(12), 614-9.
- Chiaffarino, F., Pelucchi, C., Negri, E., Parazzini, F., Franceschi, S., Talamini, R., ... & La Vecchia, C. (2005). Breastfeeding and the risk of epithelial ovarian cancer in an Italian population. *Gynecologic Oncology*, 98(2), 304-308. doi:10.1016/j.ygyno.2005.05.006.
- Claus, E. B., Schildkraut, J. M., Thompson, W. D., & Risch, N. J. (1996). The genetic attributable risk of breast and ovarian cancer. *Cancer*, 77(11), 2318-2324.
- Cohen, J. (1988). Statistical power analysis for the behavioural sciences New York, pp-22. *NY: Academic*.
- Cooper, C. P., Gelb, C. A., Trivers, K. F., & Stewart, S. L. (2016). Intended care seeking for ovarian cancer symptoms among US women. *Preventive Medicine Reports*, *3*, 234-237.
- Cooper, C. P., Polonec, L., Stewart, S. L., & Gelb, C. A. (2012). Gynaecologic cancer symptom awareness, concern and care seeking among US women: a multi-site qualitative study. *Family practice*, *30*(1), 96-104.
- Cooper, C. P., Polonec, L., & Gelb, C. A. (2011). Women's knowledge and awareness of gynecologic cancer: a multisite qualitative study in the United States. *Journal of Women's Health*, 20(4), 517-524.
- Costanzo, E. S., Lutgendorf, S. K., Sood, A. K., Anderson, B., Sorosky, J., & Lubaroff, D. M. (2005). Psychosocial factors and interleukin- 6 among women with advanced ovarian cancer. *Cancer*, 104(2), 305-313.
- Cramer, D. W. (2012). The epidemiology of endometrial and ovarian cancer. Hematology/Oncology clinics of North America, 26(1), 1-12.
- Danforth, K. N., Tworoger, S. S., Hecht, J. L., Rosner, B. A., Colditz, G. A., & Hankinson, S. E. (2007). Breastfeeding and risk of ovarian cancer in two prospective cohorts. *Cancer Causes & Control*, *18*(5), 517-523.
- Daniel, W.W. (1999). Biostatistics: A Foundation for Analysis in the Health Sciences. 7th edition. New York: John Wiley & Sons.
- de Nooijer, J., Lechner, L., & de Vries, H. (2002). Tailored versus general information on early detection of cancer: a comparison of the reactions of Dutch adults and the impact on attitudes and behaviors. *Health Education Research*, *17*(2), 239-252.
- de Nooijer, J., Lechner, L., & de Vries, H. (2001). A qualitative study on detecting cancer symptoms and seeking medical help; an application of Andersen's model of total patient delay. *Patient Education and Counseling*, 42(2), 145-157. doi:10.1016/S0738-3991(00)00104-X
- de Nooijer, J., Lechner, L., & De Vries, H. (2003). Social psychological correlates of paying attention to cancer symptoms and seeking medical help. *Social Science & Medicine*, *56*(5), 915-920.

- Dobson, C. M., Russell, A. J., & Rubin, G. P. (2014). Patient delay in cancer diagnosis: what do we really mean and can we be more specific?. *BMC Health Services Research*, *14*(1), 387.
- Drescher, C. W., Hawley, S., Thorpe, J. D., Marticke, S., McIntosh, M., Gambhir, S. S., & Urban, N. (2012). Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening. *Cancer Prevention Research*, 5(8), 1015-1024. DOI:10.1158/1940-6207.CARR-11-0468CD
- Dziura, J. D., Post, L. A., Zhao, Q., Fu, Z., & Peduzzi, P. (2013). Strategies for dealing with missing data in clinical trials: from design to analysis. *The Yale Journal of Biology and Medicine*, 86(3), 343.
- Ellison, N. B. (2007). Social network sites: Definition, history, and scholarship. *Journal* of computer- mediated Communication, 13(1), 210-230.
- Evans, J., Ziebland, S., & McPherson, A. (2007). Minimising delays in ovarian cancer diagnosis: An expansion of Andersen's model of Total patient delay'. *PSYCHO-ONCOLOGY*, 16(9), S158-S158.
- Fairfield, K. M., Willett, W. C., Rosner, B. A., Manson, J. E., Speizer, F. E., & Hankinson, S. E. (2002). Obesity, weight gain, and ovarian cancer. *Obstetrics* & *Gynecology*, 100(2), 288-296.
- Fallowfield, L., Fleissig, A., Barrett, J., Menon, U., Jacobs, I., Kilkerr, J., & Farewell, V. (2010). Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21 715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening. *British Journal of Cancer*, 103(4), 454.
- Farooqui, M., Hassali, M. A., Knight, A., Shafie, A. A., Farooqui, M. A., Saleem, F., ... & Aljadhey, H. (2013). A qualitative exploration of Malaysian cancer patients' perceptions of cancer screening. *BMC Public Health*, 13(1), 48.
- Feng, L. P., Chen, H. L., & Shen, M. Y. (2014). Breastfeeding and the risk of ovarian cancer: A Meta- Analysis. *Journal of Midwifery & Women's Health*, 59(4), 428-437.
- Ferlay, J., Héry, C., Autier, P., & Sankaranarayanan, R. (2010). Global burden of breast cancer. In *Breast Cancer Epidemiology* (pp. 1-19). Springer New York.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., ... & Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *International Journal of Cancer*, 136(5).
- Ferrell, B., Smith, S., Cullinane, C., & Melancon, C. (2003). Symptom concerns of women with ovarian cancer. *Journal of Pain and Symptom Management*, 25(6), 528-538.
- Fitch, M. I., Deane, K., Howell, D., & Gray, R. E. (2002). Women's experiences with ovarian cancer: reflections on being diagnosed. *Canadian Oncology Nursing Journal/Revue Canadienne De soins Infirmiers en Oncologie*, 12(3), 152-159.
- Forbes, L. J. L., Simon, A. E., Warburton, F., Boniface, D., Brain, K. E., Dessaix, A., ... & Lockwood, G. (2013). Differences in cancer awareness and beliefs between Australia, Canada, Denmark, Norway, Sweden and the UK (the International Cancer Benchmarking Partnership): do they contribute to differences in cancer survival?. *British Journal of Cancer*, 108(2), 292-300.
- Forbes,L.J.L., Warburton,f., Richards, M.A., & Ramirez, A.J.(2014). Rik factors for delay in symptomatic presentation: a survey of cancer patients. *British Journal* of Cancer 111,581-588 DOI:10.1038/BJC.2014.304

- Frank, T. S., Manley, S. A., Olopade, O. I., Cummings, S., Garber, J. E., Bernhardt, B., ... & Isaacs, C. (1998). Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. *Journal of Clinical Oncology*, 16(7), 2417-2425.
- Freij, M., Al Qadire, M., Khadra, M., ALBashtawy, M., Tuqan, W., Al Faqih, M., ... & Abd El-Razek, A. (2017). Awareness and Knowledge of Ovarian Cancer Symptoms and Risk Factors: A Survey of Jordanian Women. *Clinical nursing research*, 1054773817704749.
- Friedenreich, C.M. (2001). Physical activity and cancer prevention: from observation to intervention research. *Cancer Epidemiol Biomarker prev* 1; 10:287-301
- Friedman, G. D., Skilling, J. S., Udaltsova, N. V., & Smith, L. H. (2005). Early symptoms of ovarian cancer: a case–control study without recall bias. *Family* practice, 22(5), 548-553.
- Friedman, L. C., Kalidas, M., Elledge, R., Dulay, M. F., Romero, C., Chang, J., & Liscum, K. R. (2006). Medical and psychosocial predictors of delay in seeking medical consultation for breast symptoms in women in a public sector setting. *Journal of behavioral medicine*, 29(4), 327-334.
- Gentry-Maharaj, A., & Menon, U. (2012). Screening for ovarian cancer in the general population. *Best Practice & Research Clinical Obstetrics & Gynaecology*, 26(2), 243-256.
- George, E. M., Herzog, T. J., Neugut, A. I., Lu, Y. S., Burke, W. M., Lewin, S. N., ... & Wright, J. D. (2013). Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome. *Gynecologic Oncology*, 131(1), 42-45.
- Glanz, K., & Rimer, B. K. (1997). Theory at a glance: A guide for health promotion practice (No. 97). US Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute.
- Glanz, K., Rimer, B. K., & Viswanath, K. (Eds.). (2008). *Health behavior and health education: theory, research, and practice*. John Wiley & Sons.
- Global disease burden, Ovarian cancer in Malaysia. <u>http://global-disease-</u> <u>burden.healthgrove.com/l/37233/Ovarian-Cancer-in-Malaysia</u>.(Accessed: [August] [2017])
- Goff, B. (2012). Symptoms associated with ovarian cancer. *Clinical Obstetrics and Gynecology*, 55(1), 36-42. doi: 10.1097/GRF.0b013e3182480523.
- Goff, B. A., Lowe, K. A., Kane, J. C., Robertson, M. D., Gaul, M. A., & Andersen, M. R. (2012). Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptability. *Gynecologic Oncology*, *124*(2), 230-235.
- Goff, B. A., Mandel, L. S., Drescher, C. W., Urban, N., Gough, S., Schurman, K. M., ... & Andersen, M. R. (2007). Development of an ovarian cancer symptom index. *Cancer*, *109*(2), 221-227. Doi 10.1002/cncr.22371.
- Goff, B. A., Mandel, L. S., Melancon, C. H., & Muntz, H. G. (2004). Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. *Jama*, 291(22), 2705-2712.
- Goff, B. A., Mandel, L., Muntz, H. G., & Melancon, C. H. (2000). Ovarian carcinoma diagnosis. *Cancer*, 89(10), 2068-2075.
- Goldstein, C. L., Susman, E. P., Lockwood, S., Medlin, E. E., & Behbakht, K. (2015). Awareness of symptoms and risk factors of ovarian cancer in a population of women and healthcare providers. *Clinical Journal of Oncology Nursing*, 19(2).
- Green, A.E. (2016). Ovarian cancer prognosis http://emedicine.medscape.com/article/255771-overview Updated: March 22.2016. [Accessed April 7 2016]

- Quaife, S. L., Forbes, L. J., Ramirez, A. J., Brain, K. E., Donnelly, C., Simon, A. E., & Wardle, J. (2014). Recognition of cancer warning signs and anticipated delay in help-seeking in a population sample of adults in the UK. *British Journal of Cancer*, 110(1), 12.
- Hamilton, W., Peters, T. J., Bankhead, C., & Sharp, D. (2009). Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. *BMJ*, 339, b2998. doi: 10.1136/bmj.b2998.
- Hankinson, S. E., Colditz, G. A., Hunter, D. J., Willett, W. C., Stampfer, M. J., Rosner, B., ... & Speizer, F. E. (1995). A prospective study of reproductive factors and risk of epithelial ovarian cancer. *Cancer*, 76(2), 284-290.
- Hannan, L. M., Leitzmann, M. F., Lacey, J. V., Colbert, L. H., Albanes, D., Schatzkin, A., & Schairer, C. (2004). Physical activity and risk of ovarian cancer: a prospective cohort study in the United States. *Cancer Epidemiology and Prevention Biomarkers*, 13(5), 765-770.
- Hannibal, C. G., Cortes, R., Engholm, G., & Kjaer, S. K. (2008). Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978–2002. Acta Obstetricia Et Gynecologica Scandinavica, 87(12), 1353-1360.
- Hansen, R. P., Olesen, F., Sørensen, H. T., Sokolowski, I., & Søndergaard, J. (2008). Socioeconomic patient characteristics predict delay in cancer diagnosis: a Danish cohort study. *BMC Health Services Research*, 8(1), 49.
- Holman, L. L., Lu, K. H., Bast, R. C., Hernandez, M. A., Bodurka, D. C., Skates, S., & Sun, C. C. (2014). Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. *American Journal of Obstetrics* & *Gynecology*, 210(3), 257-e1.
- Holschneider, C. H., & Berek, J. S. (2000). Ovarian cancer: epidemiology, biology, and prognostic factors. In *Seminars in Surgical Oncology* (Vol. 19, No. 1, pp. 3-10). John Wiley & Sons, Inc.
- Hubbard, G., Stoddart, I., Forbat, L., Neal, R. D., O'carroll, R. E., Haw, S., ... & Kyle, R. G. (2016). School- based brief psycho- educational intervention to raise adolescent cancer awareness and address barriers to medical help- seeking about cancer: a cluster randomised controlled trial. *Psycho- Oncology*, 25(7), 760-771.
- Hvidberg, L., Pedersen, A. F., Wulff, C. N., & Vedsted, P. (2014). Cancer awareness and socio-economic position: results from a population-based study in Denmark. *BMC Cancer*, 14(1), 581.
- Iyoke, C. A., & Ugwu, G. O. (2013). Burden of gynecological cancer in developing countries WJOG, 2(1), 1-7 DOI http:// dx.doi.org/10.5317/wjog.v2.i1.1.
- Jacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K., ... & Crump, D. N. (2016). Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. *The Lancet*, *387*(10022), 945-956. doi 10.1016/ S0140-6736(15)01224-6
- Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. *CA: a cancer journal for clinicians*, *61*(2), 69-90.
- Jasen, P. (2009). From the "silent killer" to the "whispering disease": ovarian cancer and the uses of metaphor. *Medical History*, *53*(4), 489.
- Jayde, V., White, K., & Blomfield, P. (2010). Symptoms and diagnostic delay in ovarian cancer: a summary of the literature. *Contemporary Nurse*, *34*(1), 55-65.
- Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014). Ovarian cancer. *The Lancet*, *384*(9951), 1376-1388.

- Jones, S. C., & Johnson, K. (2012). Women's awareness of cancer symptoms: a review of the literature. *Women's Health*, 8(5), 579-591.
- Jones, S. C., Magee, C. A., Francis, J., Luxford, K., Gregory, P., Zorbas, H., & Iverson, D. C. (2010). Australian women's awareness of ovarian cancer symptoms, risk and protective factors, and estimates of own risk. *Cancer Causes & Control*, 21(12), 2231-2239. Doi 10.1007/s10552-010-9643-1
- Jordan, S. J., Siskind, V., Green, A. C., Whiteman, D. C., & Webb, P. M. (2010). Breastfeeding and risk of epithelial ovarian cancer. *Cancer Causes & Control*, 21(1), 109-116.
- Kaku, T., Ogawa, S., Kawano, Y., Ohishi, Y., Kobayashi, H., Hirakawa, T., & Nakano, H. (2003). Histological classification of ovarian cancer. *Medical Electron Microscopy*, 36(1), 9-17.
- Keng, S. L., Bainun, S., Wahab, A., Chiu, L. B., & Yusuf, A. (2015). Awareness of ovarian cancer risk factors among women in Malaysia : A Preliminary Study. *Asian Pac J Cancer Prev*, 16(2), 537–540.
- Kobayashi, H., Yamada, Y., Sado, T., Sakata, M., Yoshida, S., Kawaguchi, R., ... & Ueda, S. (2008). A randomized study of screening for ovarian cancer: a multicenter study in Japan. *International Journal of Gynecological Cancer*, 18(3), 414-420. doi 10.1111/j.1525-1438.2007.01035
- Koldjeski, D., Kirkpatrick, M. K., Swanson, M., Everett, L., & Brown, S. (2005). An ovarian cancer diagnosis-seeking process: unraveling the diagnostic delay problem. In *Oncology nursing forum* (Vol. 32, No. 5).
- Kuper, H., Titus- Ernstoff, L., Harlow, B. L., & Cramer, D. W. (2000). Population based study of coffee, alcohol and tobacco use and risk of ovarian cancer. *International Journal of Cancer*, 88(2), 313-318.
- Kurman, R. J., Visvanathan, K., Roden, R., Wu, T. C., & Shih, I. M. (2008). Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. *American Journal* of Obstetrics and Gynecology, 198(4), 351-356. doi: 10.1016/j.ajog.2008.01.005.
- Lacey Jr, J. V., Mink, P. J., Lubin, J. H., Sherman, M. E., Troisi, R., Hartge, P., ... & Schairer, C. (2002). Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA, 288(3), 334-341.
- Lapointe, L., Ramaprasad, J., & Vedel, I. (2014). Creating health awareness: a social media enabled collaboration. *Health and Technology*, 4(1), 43-57.
- Lataifeh, I., Marsden, D. E., Robertson, G., Gebski, V., & Hacker, N. F. (2005). Presenting symptoms of epithelial ovarian cancer. *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 45(3), 211-214.
- Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., Sessa, C., & ESMO Guidelines Working Group. (2013). Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, 24(suppl 6), vi24vi32.
- Lee, A. H., Su, D., Pasalich, M., Wong, Y. L., & Binns, C. W. (2013). Habitual physical activity reduces risk of ovarian cancer: a case–control study in southern China. *Preventive Medicine*, 57, S31-S33.
- Liu, Z., Zhang, T. T., Zhao, J. J., Qi, S. F., Du, P., Liu, D. W., & Tian, Q. B. (2015). The association between overweight, obesity and ovarian cancer: a metaanalysis. *Japanese Journal of Clinical Oncology*, 45(12), 1107-1115.

- Lockwood-Rayermann, S., Donovan, H. S., Rambo, D., & Kuo, C. W. J. (2009). Women's awareness of ovarian cancer risks and symptoms. *AJN The American Journal of Nursing*, 109(9), 36-45.
- Low, E. L., Waller, J., Menon, U., Jones, A., Reid, F., & Simon, A. E. (2013). Ovarian cancer symptom awareness and anticipated time to help-seeking for symptoms among UK women. J Fam Plann Reprod Health Care, 39(3), 163-171. doi:10.1136/jfprhc-2012-100473.
- Luan, N. N., Wu, Q. J., Gong, T. T., Vogtmann, E., Wang, Y. L., & Lin, B. (2013). Breastfeeding and ovarian cancer risk: a meta-analysis of epidemiologic studies. *The American Journal of Clinical Nutrition*, ajcn-062794.
- Lurie, G., Thompson, P. J., McDuffie, K. E., Carney, M. E., & Goodman, M. T. (2009). Prediagnostic symptoms of ovarian carcinoma: a case-control study. *Gynecologic Oncology*, 114(2), 231-236.
- Lutz, A.M., Willmann, J.K., Dresche, r C.W., Ray, P., Cochran, F.V., Urban, N., Gambhir, S.S. (2011). Early diagnosis of ovarian carcinoma: Is a solution in sight?.*Radiology* 259(2):329-45. Doi: 10.1148?radiol.11090563
- Lutgendorf, S. K., Sood, A. K., Anderson, B., McGinn, S., Maiseri, H., Dao, M., ... & Lubaroff, D. M. (2005). Social support, psychological distress, and natural killer cell activity in ovarian cancer. *Journal of Clinical Oncology*, 23(28), 7105-7113.
- Macleod, U., Mitchell, E. D., Burgess, C., Macdonald, S., & Ramirez, A. J. (2009). Risk factors for delayed presentation and referral of symptomatic cancer: evidence for common cancers. *British Journal of Cancer*, 101(Suppl 2), S92.
- McGowan, L., Norris, H. J., Hartge, P., Hoover, R., & Lesher, L. (1988). Risk factors in ovarian cancer. *European Journal of Gynaecological Oncology*, 9(3), 195-199.
- McLaughlin, J. R., Risch, H. A., Lubinski, J., Moller, P., Ghadirian, P., Lynch, H., ... & Offit, K. (2007). Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. *The Lancet Oncology*, 8(1), 26-34.
- Menon, U., Griffin, M., & Gentry-Maharaj, A. (2014). Ovarian cancer screening current status, future directions. *Gynecologic Oncology*, *132*(2), 490-495.
- Menon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., ... & Godfrey, K. (2009). Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *The Lancet Oncology*, 10(4), 327-340. doi: 10.1060/S1470-2045(09)70026-9.
- Modugno, F., & Presenters, H. R. W. S. (2003). Ovarian cancer and high-risk women implications for prevention, screening, and early detection. *Gynecologic Oncology*, 91(1), 15-31. doi; 10.1016/s0090-8258(03)00254-3
- Moffat, J., Hinchliffe, R., Ironmonger, L., & Osborne, K. (2016). Identifying anticipated barriers to help-seeking to promote earlier diagnosis of cancer in Great Britain. *Public Health*, 141, 120-125.
- Molassiotis, A., Wilson, B., Brunton, L., & Chandler, C. (2010). Mapping patients' experiences from initial change in health to cancer diagnosis: a qualitative exploration of patient and system factors mediating this process. *European Journal of Cancer Care*, 19(1), 98-109 . doi: 10.1111/j.1365-2354.2008.01020.x
- Moorman, P. G., Jones, L. W., Akushevich, L., & Schildkraut, J. M. (2011). Recreational physical activity and ovarian cancer risk and survival. *Annals of Epidemiology*, 21(3), 178-187.

- Moore, M. A., Manan, A. A., Chow, K. Y., Cornain, S. F., Devi, C. R., Triningsih, F. X., ... & Nyunt, K. (2010). Cancer epidemiology and control in peninsular and island South-East Asia-past, present and future. *Asian Pac J Cancer Prev*, 11(Suppl 2), 81-98.
- Morris, M., Smith, C. F., Boxell, E., Wardle, J., Simon, A., & Waller, J. (2016). Quantitative evaluation of an information leaflet to increase prompt helpseeking for gynaecological cancer symptoms. *BMC Public Health*, 16(1), 374. doi: 10.1186/s12889-016-3032-y.
- Morris, C. R., Sands, M. T., & Smith, L. H. (2010). Ovarian cancer: predictors of earlystage diagnosis. *Cancer Causes & Control*, 21(8), 1203-1211. Doi: 10.1007/s10552-010-9547-0
- Moyer, V. A. (2012). Screening for prostate cancer: US Preventive Services Task Force recommendation statement. *Annals of Internal Medicine*, *157*(2), 120-134.
- Narod, S. A., Risch, H., Moslehi, R., Dørum, A., Neuhausen, S., Olsson, H., ... & Brunet, J. S. (1998). Oral contraceptives and the risk of hereditary ovarian cancer. *New England Journal of Medicine*, 339(7), 424-428.
- National Cancer Institute, NCI Dictionary Cancer Term. From https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=445074
- National Cancer Registry report: Malaysia cancer statisitcs- data & figure 2011. www.care.upm.edu.my/dokumen/13603\_NCR2007.pdf
- Neal, R. D., Tharmanathan, P., France, B., Din, N. U., Cotton, S., Fallon-Ferguson, J., ... & Macleod, U. (2015). Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. *British Journal of Cancer*, 112(Suppl 1), S92. doi 10.1038/bjc.2015.48.
- Niksic, M., Rachet, B., Warburton, F. G., Wardle, J., Ramirez, A. J., & Forbes, L. J. (2015). Cancer symptom awareness and barriers to symptomatic presentation in England—are we clear on cancer?. *British journal of cancer*, 113(3), 533.
- Norsa'adah, B., Rahmah, M. A., Rampal, K. G., & Knight, A. (2012). Understanding barriers to Malaysian women with breast cancer seeking help. *Asian Pacific Journal of Cancer Prevention*, 13(8), 3723-3730.
- Noordzij, M., Tripepi, G., Dekker, F. W., Zoccali, C., Tanck, M. W., & Jager, K. J. (2010). Sample size calculations: basic principles and common pitfalls. *Nephrology Dialysis Transplantation*, 25(5), 1388-1393.
- O'connor, P. J., Martin, B., Weeks, C. S., & Ong, L. (2014). Factors that influence young people's mental health help- seeking behaviour: a study based on the Health Belief Model. *Journal of Advanced Nursing*, *70*(11), 2577-2587.
- Official portal of Uuniversiti Putra Malaysia, Facts & Figures, 2017. From http://www.upm.edu.my/about\_us/facts\_figures/facts\_figures-8289?L=en.
- Official Portal of office of vice chancellor, UPM, Appointment of administrative post, 2017. From http://www.pnc.upm.edu.my/our services/appointment of administrative po
  - st-5560
- Olesen, F., Hansen, R. P., & Vedsted, P. (2009). Delay in diagnosis: the experience in Denmark. *British Journal of Cancer*, 101(Suppl 2), S5. doi: 10.1038/sj.bjc.6605383.
- Pallant, J. (2011). Survival manual. A Step By Step Guide to Data Analysis Using SPSS.
- Pasalich, M., Su, D., Binns, C. W., & Lee, A. H. (2013). Reproductive factors for ovarian cancer in southern Chinese women. *Journal of gynecologic oncology*, 24(2), 135-140.

- Park, Y. S., & Park, J. S. (2016). Awareness and Health Belief of Ovarian Cancer among Women in an Urban Area. *Journal of the Korean Society of Maternal and Child Health*, 20(3), 239-252.
- Payne, H. E., Lister, C., West, J. H., & Bernhardt, J. M. (2015). Behavioral functionality of mobile apps in health interventions: a systematic review of the literature. *JMIR mHealth and uHealth*, *3*(1).
- Peterson, N. B., Trentham- Dietz, A., Newcomb, P. A., Chen, Z., Hampton, J. M., Willett, W. C., & Egan, K. M. (2006). Alcohol consumption and ovarian cancer risk in a population- based case–control study. *International Journal of Cancer*, 119(10), 2423-2427. doi: 10.1002/ijc.22137
- Polit, D. F., & Beck, C. T. (2006). The content validity index: are you sure you know what's being reported? Critique and recommendations. *Research in Nursing & Health*, 29(5), 489-497.
- Prat, J. (2014). For the FIGO committee on gynecologic oncology. Staging classification for cancer of the ovary, Fallopian tube/and peritoneum. *Int J Gynecol Obstet* 124:1-5
- Puckett, M. C., Townsend, J. S., Gelb, C. A., Hager, P., Conlon, A., & Stewart, S. L. (2017). Ovarian Cancer Knowledge in Women and Providers Following Education with Inside Knowledge Campaign Materials. *Journal of Cancer Education*, 1-9.
- Quaife, S. L., Forbes, L. J., Ramirez, A. J., Brain, K. E., Donnelly, C., Simon, A. E., & Wardle, J. (2014). Recognition of cancer warning signs and anticipated delay in help-seeking in a population sample of adults in the UK. *British journal of cancer*, 110(1), 12-18.
- Rahaei, Z., Ghofranipour, F., Morowatisharifabad, M. A., & Mohammadi, E. (2015). Determinants of cancer early detection behaviors: application of protection motivation theory. *Health Promotion Perspectives*, 5(2), 138. doi: 10.15171/hpp.2015.016
- Rakowski, W., Ehrich, B., Goldstein, M. G., Rimer, B. K., Pearlman, D. N., Clark, M. A., ... & Woolverton, H. (1998). Increasing mammography among women aged 40–74 by use of a stage-matched, tailored intervention. *Preventive medicine*, 27(5), 748-756.
- Ramirez, A. J., Westcombe, A. M., Burgess, C. C., Sutton, S., Littlejohns, P., & Richards, M. A. (1999). Factors predicting delayed presentation of symptomatic breast cancer: a systematic review. *The Lancet*, 353(9159), 1127-1131.
- Razi, S., Ghoncheh, M., Mohammadian-Hafshejani, A., Aziznejhad, H., Mohammadian,
   M., & Salehiniya, H. (2016). The incidence and mortality of ovarian cancer and their relationship with the Human Development Index in Asia. *Ecancermedicalscience*, 10,628 doi:10.3332/ecancer.2016.628.
- Reade, C. J., Riva, J. J., Busse, J. W., Goldsmith, C. H., & Elit, L. (2013). Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. *Gynecologic Oncology*, 130(3), 674-681.
- Rim, S. H., Polonec, L., Stewart, S. L., & Gelb, C. A. (2011). A national initiative for women and healthcare providers: CDC's inside knowledge: get the facts about gynecologic cancer campaign. *Journal of Women's Health*, 20(11), 1579-1585.
- Riman, T., Dickman, P. W., Nilsson, S., Correia, N., Nordlinder, H., Magnusson, C. M., & Persson, I. R. (2002). Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. *American Journal of Epidemiology*, 156(4), 363-373. Doi:10.1093/aje/kwf048.

- Ristvedt, S. L., & Trinkaus, K. M. (2005). Psychological Factors Related to Delay in Consultation for Cancer Symptoms. *Psycho-Oncology*, 14(5), 339–350. <u>http://doi.org/10.1002/pon.850</u>
- Robb, K., Stubbings, S., Ramirez, A., Macleod, U., Austoker, J., Waller, J., ... & Wardle, J. (2009). Public awareness of cancer in Britain: a population-based survey of adults. *British Journal of Cancer*, 101(Suppl 2), S18.
- Robinson, K. M., Ottesen, B., Christensen, K. B., & Krasnik, A. (2009). Diagnostic delay experienced among gynecological cancer patients: a nationwide survey in Denmark. Acta Obstetricia Et Gynecologica Scandinavica, 88(6), 685-692.
- Rosenstock, I. M., Strecher, V. J., & Becker, M. H. (1988). Social learning theory and the health belief model. *Health Education Quarterly*, *15*(2), 175-183.
- Rufford, B. D., Jacobs, I. J., & Menon, U. (2007). Feasibility of screening for ovarian cancer using symptoms as selection criteria. *BJOG: An International Journal of Obstetrics & Gynaecology*, *114*(1), 59-64. doi: 10.1111/J.1471-0528.2006.01153.x
- Ruiter, R. A., de Nooijer, J., van Breukelen, G., Ockhuysen-Vermey, C. F., & deVries, H. (2008). Intended coping responses to cancer symptoms in healthy adults: the roles of symptom knowledge, detection behavior, and perceived threat. *Cancer Epidemiology and Prevention Biomarkers*, 17(4), 818-826.
- Ryerson, A. B., Eheman, C., Burton, J., McCall, N., Blackman, D., Subramanian, S., & Richardson, L. C. (2007). Symptoms, diagnoses, and time to key diagnostic procedures among older US women with ovarian cancer. *Obstetrics & Gynecology*, 109(5), 1053-1061.
- Sankaranarayanan, R., & Ferlay, J. (2006). Worldwide burden of gynaecological cancer: the size of the problem. *Best Practice & Research Clinical Obstetrics & Gynaecology*, 20(2), 207-225.
- Saunders, C. L., Chiodini, B. D., Sham, P., Lewis, C. M., Abkevich, V., Adeyemo, A. A., ... & Boehnke, M. (2007). Meta- Analysis of Genome- wide Linkage Studies in BMI and Obesity. *Obesity*, 15(9), 2263-2275.
- Schulz, M., Lahmann, P. H., Boeing, H., Hoffmann, K., Allen, N., Key, T. J., ... & Hallmans, G. (2005). Fruit and vegetable consumption and risk of epithelial ovarian cancer: the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiology and Prevention Biomarkers*, 14(11), 2531-2535.
- Scott, S. E., Grunfeld, E. A., Auyeung, V., & McGurk, M. (2009). Barriers and triggers to seeking help for potentially malignant oral symptoms: implications for interventions. *Journal of Public Health Dentistry*, 69(1), 34-40. doi: 10.1111/j.1752-7325.2008.00095.x
- Scully, R. E. (1999). Histological classification of ovarian tumours. In *Histological Typing of Ovarian Tumours* (pp. 3-9). Springer Berlin Heidelberg.
- Seibaek, L., Petersen, L. K., Blaakaer, J., & Hounsgaard, L. (2011). Symptom interpretation and health care seeking in ovarian cancer. *BMC Women's Health*, *11*(1), 31. doi: 10.1186/1472-6874-11-31.
- Shankar, A., Rath, G., Roy, S., Malik, A., Bhandari, R., Kishor, K., ... & Singh, R. (2014). Level of awareness of cervical and breast cancer risk factors and safe practices among college teachers of different states in india: do awareness programmes have an impact on adoption of safe practices?. Asian Pacific Journal of Cancer Prevention: APJCP, 16(3), 927-932.
- Sheeran, P. (2002). Intention—behavior relations: A conceptual and empirical review. *European Review of Social Psychology*, *12*(1), 1-36.

- Sieh, W., Salvador, S., McGuire, V., Weber, R. P., Terry, K. L., Rossing, M. A., ... & Doherty, J. A. (2013). Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. *International Journal of Epidemiology*, 42(2), 579-589.
- Simon, A. E., Forbes, L. J., Boniface, D., Warburton, F., Brain, K. E., Dessaix, A., ... & Petermann, L. (2012a). An international measure of awareness and beliefs about cancer: development and testing of the ABC. *BMJ Open*, 2(6), e001758.
- Simon, A. E., Wardle, J., Grimmett, C., Power, E., Corker, E., Menon, U., ... & Waller, J. (2012b). Ovarian and cervical cancer awareness: development of two validated measurement tools. *Journal of Family Planning and Reproductive Health Care*, 38(3), 167-174.
- Simon, A. E., Waller, J., Robb, K. A., & Wardle, J. (2010). Patient delay in presentation of possible cancer symptoms: the contribution of knowledge and attitudes in a UK population sample. *Cancer Epidemiology and Prevention Biomarkers*, cebp-0219.
- Skinner, C. S., Strecher, V. J., & Hospers, H. (1994). Physicians' recommendations for mammography: do tailored messages make a difference?. *American Journal of Public Health*, 84(1), 43-49.
- Smith, E. M., & Anderson, B. (1985). The effects of symptoms and delay in seeking diagnosis on stage of disease at diagnosis among women with cancers of the ovary. *Cancer*, 56(11), 2727-2732.
- Smith, L. K., Pope, C., & Botha, J. L. (2005). Patients' help-seeking experiences and delay in cancer presentation: a qualitative synthesis. *The Lancet*, 366(9488), 825-831.
- Sood, A. K., Bhatty, R., Kamat, A. A., Landen, C. N., Han, L., Thaker, P. H., ... & Cole, S. W. (2006). Stress hormone-mediated invasion of ovarian cancer cells. *Clinical Cancer Research*, 12(2), 369-375.
- Stavraka, C., Ford, A., Ghaem-Maghami, S., Crook, T., Agarwal, R., Gabra, H., & Blagden, S. (2012). A study of symptoms described by ovarian cancer survivors. *Gynecologic Oncology*, 125(1), 59-64. doi 10.1016/j.ygyno.2011.12.421
- Stewart, S. L. (2012). Ovarian cancer incidence: current and comprehensive statistics. INTECH Open Access Publisher.
- Stratton, J. F., Pharoah, P., Smith, S. K., Easton, D., & Ponder, B. A. (1998). A systematic review and meta- analysis of family history and risk of ovarian cancer. BJOG: An International Journal of Obstetrics & Gynaecology, 105(5), 493-499.
- Stubbings, S., Robb, K., Waller, J., Ramirez, A., Austoker, J., Macleod, U., ... & Wardle, J. (2009). Development of a measurement tool to assess public awareness of cancer. *British Journal of Cancer*, 101(Suppl 2), S13. doi: 10.1038/sj.bjc.6605385.
- Su, Z., Graybill, W. S., & Zhu, Y. (2013). Detection and monitoring of ovarian cancer. *Clinica Chimica Acta*, 415, 341-345.doi: 10.1016/j.cca.2012.10.058
- Tejada-Bergés, T., Trimble, E. L., & Shetty, M. K. (2013). Ovarian Cancer Screening and Early Detection in Low-and Middle-Income Countries. In *Breast and Gynecological Cancers* (pp. 125-148). Springer New York.
- Taplin, S. H., Anderman, C., Grothaus, L., Curry, S., & Montano, D. (1994). Using physician correspondence and postcard reminders to promote mammography use. *American Journal of Public Health*, 84(4), 571-574.

- Thackeray, R., Neiger, B. L., Smith, A. K., & Van Wagenen, S. B. (2012). Adoption and use of social media among public health departments. *BMC public health*, *12*(1), 242.
- Thulesius, H. O., Lindgren, A. C., Olsson, H. L., & Håkansson, A. (2004). Diagnosis and prognosis of breast and ovarian cancer A population-based study of 234 women. *Acta Oncologica*, 43(2), 175-181.
- Trivers, K. F., Rodriguez, J. L., Hawkins, N. A., Polonec, L., Gelb, C. A., & Cooper, C. P. (2011). Peer Reviewed: Intention to Seek Care for Symptoms Associated With Gynecologic Cancers, HealthStyles Survey, 2008. *Preventing Chronic Disease*, 8(6).
- Tsilidis, K. K., Allen, N. E., Key, T. J., Dossus, L., Lukanova, A., Bakken, K., ... & Tjønneland, A. (2011). Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. *British Journal of Cancer*, 105(9), 1436-1442.
- Tworoger, S. S., Gertig, D. M., Gates, M. A., Hecht, J. L., & Hankinson, S. E. (2008). Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. *Cancer*, 112(5), 1169-1177.
- Urban, N., & Drescher, C. (2008). Potential and limitations in early diagnosis of ovarian cancer. In *Ovarian Cancer* (pp. 3-14). Springer, New York, NY.
- Van Der Velde, N. M., Mourits, M. J., Arts, H. J., de Vries, J., Leegte, B. K., Dijkhuis, G., ... & de Bock, G. H. (2009). Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?. *International Journal of Cancer*, *124*(4), 919-923.
- Van Osch, L., Lechner, L., Reubsaet, A., de Nooijer, J., & De Vries, H. (2007). Passive cancer detection and medical help seeking for cancer symptoms:(in) adequate behavior and psychosocial determinants. *European Journal of Cancer Prevention*, *16*(3), 266-274.
- Vine, M. F., Calingaert, B., Berchuck, A., & Schildkraut, J. M. (2003). Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. *Gynecologic Oncology*, *90*(1), 75-82.
- Varadheswari, T., Dandekar, R. H., & Sharanya, T. (2015). A study on the prevalence and KAP regarding cervical cancer among women attending a tertiary care hospital in Perambalur. *Int J Prev Med Res*, *1*, 71-78.
- Vargas, A. N. (2014). Natural history of ovarian cancer. Ecancermedicalscience, 8.
- Walter, F., Webster, A., Scott, S., & Emery, J. (2012). The Andersen Model of Total Patient Delay: a systematic review of its application in cancer diagnosis. *Journal of Health Services Research & Policy*, 17(2), 110-118.
- Wantland, D. J., Portillo, C. J., Holzemer, W. L., Slaughter, R., & McGhee, E. M. (2004). The effectiveness of Web-based vs. non-Web-based interventions: a metaanalysis of behavioral change outcomes. *Journal of medical Internet research*, 6(4).
- Webb, P. M., Purdie, D. M., Grover, S., Jordan, S., Dick, M. L., & Green, A. C. (2004). Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. *Gynecologic Oncology*, 92(1), 232-239.
- Whittemore, A., Harris, R., & Itnyr, e.J.(1992). Characteristics relating to ovarian cancer risk. Collaborative analysis of 12 US Case- control studies.IV. The pathogeneses of ovarian cancer. Group of the Collaborative Ovarian Cancer. *Am j Epidemiol* 15;136(10):1212-20.
- Whitaker, K. L., Scott, S. E., & Wardle, J. (2015). Applying symptom appraisal models to understand sociodemographic differences in responses to possible cancer symptoms: a research agenda. *British Journal of Cancer*, *112*, S27-S34.

- Wikborn, C., Pettersson, F., & Moberg, P. J. (1996). Delay in diagnosis of epithelial ovarian cancer. *International Journal of Gynecology & Obstetrics*, 52(3), 263-267.
- Wong, L. P., Wong, Y. L., Low, W. Y., Khoo, E. M., & Shuib, R. (2009). Knowledge and awareness of cervical cancer and screening among Malaysian women who have never had a Pap smear: a qualitative study. *Singapore Medical Journal*, 50(1), 49.
- Wooster, R., & Weber, B. L. (2003). Breast and ovarian cancer. *New England Journal* of Medicine, 348(23), 2339-2347.
- Yancik, R. (1993). Ovarian cancer; Age contrasts in incidence, history, disease stage at diagnosis and mortality. *Cancer*, 71,517-523. doi: 10.1002/cncr.2820710205
- Yawn, B.P., Barrette, B.A., & Wollan, P.C. (2004). Ovarian cancer: the neglected diagnosis. *Mayo Clin Proc* ; 79(10):1277-82.
- Yimer, M., Abera, B., Mulu, W., & Bezabih, B. (2014). Knowledge, attitude and practices of high risk populations on louse-borne relapsing fever in Bahir Dar city, north-west Ethiopia. *Science Journal of Public Health*, *2* (1), 15-22